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HUMAN GENE-EDITING RESEARCH: IS THE
FUTURE HERE YET?*
NANCY M. P. KING**
Since the discovery of DNA, researchers have pursued the
prospect of correcting genetic disorders using genetic
interventions. The most recent development, gene editing, poses
many scientific, medical, ethical, and policy challenges, especially
when the goal is editing the genomes of embryos, creating
changes that can be inherited by future generations. Genetic
treatments for already-born persons are not controversial, but
inheritable genetic changes raise concerns about dangerous
outcomes, questions about how to prioritize among scientific and
societal needs, and worries about pursuing genetic changes that
are enhancements rather than treatments for disease. The history
of genetic-intervention research and the development of geneediting tools like CRISPR were complicated enough, even before
the “CRISPR babies” controversy arose in late 2018. CRISPR
and related editing technologies should be used for basic
research in order to learn more about human development and
disease, but there is considerable disagreement and reason to be
cautious about clinical applications. Moreover, no global
enforcement mechanism exists to detect and prevent deviations
from policy. Improved transparency, robust ongoing discussion,
and increased education in ethics and genetics for scientists,
students, and the public may therefore be both achievable goals
and best practices for this rapidly developing science.
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INTRODUCTION
Gene editing is the technical process of deleting segments of
DNA from an organism’s genes, and sometimes substituting new
DNA sequences, in order to eliminate deleterious mutations. 1
Advances in gene-editing technology have renewed hopes of
correcting genetic defects in humans and rekindled debates about the
many ethical, social, and policy consequences of genetic
manipulation, especially when changes will be passed on through the
germline, that is, to future generations. Gene-editing tools like
CRISPR-associated protein 9 (“CRISPR-Cas9”) are potentially
precise, accurate, easy, quick, and cheap. As a result, gene editing has
also renewed long-standing debates about efforts to pursue human
1. Nonscientists will welcome the accessibility, comprehensive history, and sweeping
survey of ethical and policy issues raised by gene editing in a highly readable book by one
of the discoverers of CRISPR. See generally JENNIFER A. DOUDNA & SAMUEL H.
STERNBERG, A CRACK IN CREATION: GENE EDITING AND THE UNTHINKABLE POWER
TO CONTROL EVOLUTION (2017). For a shorter and equally accessible overview, see
Jennifer Kahn, The CRISPR Quandary, N.Y. TIMES MAG. (Nov. 9, 2015),
https://www.nytimes.com/2015/11/15/magazine/the-crispr-quandary.html [https://perma.cc/
9YW3-BCVQ (dark archive)]. In addition, students of popular culture may appreciate two
YouTube videos about CRISPR. See acapellascience, CRISPR-Cas9 (“Mr. Sandman”
Parody) | A Capella Science, YOUTUBE (Oct. 8, 2016), https://www.youtube.com/
watch?v=k99bMtg4zRk [https://perma.cc/W9PK-PG39]; LastWeekTonight, Gene Editing:
Last Week Tonight with John Oliver (HBO), YOUTUBE (July 1, 2018),
https://www.youtube.com/watch?v=AJm8PeWkiEU [https://perma.cc/4C2M-DE6V].
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germline alteration and enhancement. These debates reached fever
pitch in late November 2018, when Chinese scientist Dr. He Jiankui
claimed to the world that he had accomplished genome editing of two
zygotes successfully brought to term as twin girls.2 At first it was
unclear whether the twins actually existed, but it became increasingly
clear that Dr. He had lied, ignored ethics guidelines, and cut
regulatory corners at best, and that the purported edits were probably
ineffective and possibly dangerous.3
This Article examines the new gene-editing boom, considering
briefly a range of issues—namely, the safety, efficacy, affordability,
ethical and social acceptability, oversight, and control of this novel
biotechnology. Part I, a very basic introduction to the science of gene
editing, notes the similarities and differences between gene editing
and its predecessor, gene transfer or gene addition, and a potential
successor, base editing. This part continues by examining the policy
furor that followed the first publications reporting about gene-editing
research efforts in human embryos. It concludes that keeping up with
the science and managing its oversight have become significant
challenges for policymakers and bioethics scholars. Part II considers
the prospect of human gene editing in its social and historical context,
examining the most recent scientific developments and the policy
debates engendered thereby, including the recent, unexpected, and
highly controversial reported birth of gene-edited twins in China. Part
III then discusses ethical and policy debates and future prospects for
ethical consensus on whether, where, when, and how to move forward
with human gene-editing research and clinical translation applied to
embryos intended for birth. This part addresses somatic versus
germline editing and gene editing’s connection to and dependence on
basic assisted reproduction technologies like in vitro fertilization
2. See infra notes 83–98 and accompanying text.
3. Dr. He’s claims were first brought to public attention in late November 2018. See
Antonio Regalado, Exclusive: Chinese Scientists Are Creating CRISPR Babies, MIT TECH.
REV. (Nov. 25, 2018), https://www.technologyreview.com/s/612458/exclusive-chinesescientists-are-creating-crispr-babies/ [https://perma.cc/9FLZ-3UJ4] [hereinafter Regalado,
Chinese Scientists]. Also on November 25, Dr. He released a YouTube video about his
claims. The He Lab, About Lulu and Nana: Twin Girls Born Healthy After Gene Surgery
as Single-Cell Embryos, YOUTUBE (Nov. 25, 2018), https://www.youtube.com/
watch?v=th0vnOmFltc [https://perma.cc/H3XM-EE97]. For a summary of Dr. He’s claims
and responses to those claims, see Sharon Begley & Andrew Joseph, The CRISPR
Shocker: How Genome Editing Scientist He Jiankui Rose from Obscurity to Stun the
World, STAT (Dec. 17, 2018), https://www.statnews.com/2018/12/17/crispr-shockergenome-editing-scientist-he-jiankui/ [https://perma.cc/ARU5-US4N]; see also infra notes
86–98 and accompanying text.
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(“IVF”) and preimplantation genetic diagnosis (“PGD”), including
controversial arguments about the necessity of germline alteration.
This part also addresses treatment versus enhancement and questions
of governance and access. Part IV suggests the need to refocus
emphasis on modeling and adhering to careful, meticulous, and
responsible science, as taught and practiced in laboratories around
the world, in both preclinical and translational research settings.
Responsible science, fostered by good education in sound and ethical
scientific practice, has the best chance—if there is any chance—of
promoting the conduct of reason-grounded and thoughtful research,
and of helping to ensure robust public discussion of and policy
deliberation about ethically sound scientific progress.
I. THE SCIENCE AND EARLY HISTORY OF GENE EDITING
Gene editing has captured the public imagination since CRISPR
first hit the news just a few years ago.4 It is noteworthy, however, that
most of the scientific, medical, ethical, and policy issues raised by
gene editing echo questions and problems that have been discussed
since Watson, Crick, and Franklin first identified the double helix.5
This Article addresses some of the most significant implications of
future human clinical applications of gene editing.6
4. See supra note 1.
5. Tracy Hampton, Ethical and Societal Questions Loom Large as Gene Editing
Moves Closer to the Clinic, 315 JAMA 546, 546–48 (2016). The deoxyribonucleic acid
(“DNA”) helix was identified in 1953. By the 1970s, the search for effective gene-based
treatments for human genetic diseases had begun in earnest. Mary Carrington Coutts,
Human Gene Therapy, 4 KENNEDY INST. ETHICS J. 63, 65 (1994) The first human patientsubject, Ashanti de Silva, received a gene-transfer (now often referred to as gene
augmentation) intervention in 1990. Id. at 63. In 1999, Jesse Gelsinger became the first
patient-subject to die as a result of a gene-transfer research intervention. Rick Weiss &
Deborah Nelson, Methods Faulted in Gene Test Death: Teen Too Ill for Therapy, Probe
Finds, WASH. POST, Dec. 8, 1999, at A1; Paul Gelsinger, Jesse’s Intent, GUINEA PIG ZERO
(2000), http://www.guineapigzero.com/jesses-intent.html [https://perma.cc/R5PG-8S3X].
The first gene-transfer intervention was approved as a therapy in 2004 in China. Sue
Pearson, Hepeng Jia & Keiko Kandachi, China Approves First Gene Therapy, 22 NATURE
BIOTECHNOLOGY 3, 3–4 (2004). A few more gene-transfer interventions have been
approved to date as therapies by the European Medicines Agency (“EMA”), see Nuala
Moran, First Gene Therapy Glybera (Finally) Gets EMA Approval, BIOWORLD (Nov. 2,
2012), http://www.bioworld.com/content/first-gene-therapy-glybera-finally-gets-ema-approval-1
[https://perma.cc/5BQN-U4FT], and the FDA, News Release, FDA, FDA Approves Novel
Gene Therapy to Treat Patients with a Rare Form of Inherited Vision Loss (Dec. 19,
2017), https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm589467.htm
[https://perma.cc/LSH7-YNEN].
6. This Article draws on some of my previous work on gene editing and related
novel biotechnologies, most notably Nancy M. P. King, Pat C. Lord & Douglas E. Lemley,
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A. Science and Ethics in a Fast-Moving Field
Researchers have been attempting to “edit” genes, by deleting
harmful genes and replacing them in the genome with nonmutated
versions, since the 1990s.7 The tools and techniques first used in gene
editing, zinc finger nucleases (“ZFNs”) and transcription activatorlike effector nucleases (“TALENs”), are complex and difficult to
master; their slow progress thus attracted little notice.8 But then came
CRISPR (clustered regularly interspersed palindromic repeats),
which was first discovered as an adaptive immune system in bacteria
but was quickly modified to specifically target any DNA sequence.9
Since mid-2014, the explosion of scientific, medical, and public

Editing the Genome: Prospects, Progress, Implications, and Cautions, 5 CURRENT
GENETIC MED. REP. 35, 35–43 (2017). It is unfortunately not possible, however, to
address all or even most of the relevant issues without taking up excessive space and trying
readers’ patience. Many significant ethical and policy issues arise from applications of
gene editing (and gene drives) to plants and animals. These issues include not only
agricultural and animal husbandry applications but also basement biohacking and the
potential weaponization of genetically altered organisms. All this and more is well beyond
the scope of this Article, yet others have given these topics expert treatment. See generally
NAT’L ACADS. OF SCIS., ENG’G, & MED., GENE DRIVES ON THE HORIZON (2016)
(summarizing the scientific discoveries related to gene drives and considerations for their
responsible use); Sharon Begley, Monsanto Licenses CRISPR Technology to Modify
Crops—with Key Restrictions, STAT (Sept. 22, 2016), https://www.statnews.com/2016/09/
22/monsanto-licenses-crispr/ [https://perma.cc/G3MS-FKG3]. Nor do I address the
prospect of using gene editing and related technologies to create human-animal chimeras,
such as “humanized” pigs capable of growing human organs suitable for transplantation,
which raises issues that are related to but distinguishable from those addressed in this
Article and that deserve thorough examination. See, e.g., David Shaw et al., Creating
Human Organs in Chimaera Pigs: An Ethical Source of Immunocompatible Organs?, 41 J.
MED. ETHICS 970, 970–74 (2015); Fergus Walsh, US Bid to Grow Human Organs for
Transplant Inside Pigs, BBC NEWS (June 6, 2016), www.bbc.com/news/health-36437428
[https://perma.cc/PD7N-TT6L].
7. See Jens Boch, TALEs of Genome Targeting, NATURE BIOTECHNOLOGY 135,
135–36 (2011); Sundar Durai et al., Zinc Finger Nucleases: Custom-Designed Molecular
Scissors for Genome Engineering of Plant and Mammalian Cells, 33 NUCLEIC ACIDS RES.
5978, 5978 (2005).
8. Even so, close to a dozen protocols involving ZFNs have been submitted to the
Recombinant DNA Advisory Committee (“RAC”) for review to date. See, e.g., Gene
Transfer Protocol Report: A Phase I, Open-Label, Ascending Dose Study to Assess the
Safety and Tolerability of AAV2/6 Factor IX Gene Therapy via Zinc Finger Nuclease
(ZFN) Mediated Targeted Integration of SB-FIX in Adult Subjects with Severe Hemophilia
B, GEMCRIS (Jan. 23, 2018), https://www.gemcris.od.nih.gov/Contents/GC_CLIN_
TRIAL_RPT_VIEW.asp?WIN_TYPE=R&CTID=1446
[https://perma.cc/7ER8-X557].
Moreover, TALEN, although nowhere near approval as a therapy, has been used to treat
an infant outside the United States, apparently successfully. See Andrew Pollack, A Cell
Therapy Untested in Humans Saves a Baby with Cancer, N.Y. TIMES, Nov. 6, 2015, at B3.
9. Kahn, supra note 1.
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interest has resulted in thousands of scholarly publications,10 floods of
articles in the popular press,11 and extensive debate about a broad
range of bioethics and public policy issues, including but not limited
to questions about safety and efficacy, about whether it is appropriate
to edit the human germline,12 and about whether it is possible to
establish global governance over what appears to be a potentially
species-altering technology.13 Federal and international panels and
commissions have addressed the science and ethics of CRISPR.14 And
public discussion of the possibility and desirability of making
inheritable genetic alterations to eliminate genetic disease, and of
genetically enhancing humans, which has been simmering for nearly
fifty years, has now reached boiling point.

10. See, e.g., Barry L. Stoddard & Keith Fox, Editorial, CRISPR in Nucleic Acids
Research, 44 NUCLEIC ACIDS RES. 4989, 4989–90 (2016), corrected at 44 NUCLEIC ACIDS
RES. 8512, 8512 (2016) (correcting an omission of a reference from a previous issue to
properly explain that “the number of studies citing ‘CRISPR + Cas9,’ as indexed in
PubMed, has exploded from four papers in 2012 to a projection of over 2000 publications
in 2016”); Amanda B. Keener, Gene Editing: From Roots to Riches, SCIENTIST (Oct. 1,
2016), http://www.the-scientist.com/?articles.view/articleNo/47156/title/Gene-Editing--FromRoots-to-Riches/ [https://perma.cc/5ZZ9-NNHZ].
11. See, e.g., Kendal K. Morgan, CRISPR Comes to the Clinic, GENOME MAG.,
Summer 2017, at 40, 43, 45; Alice Park, Life, the Remix, TIME, July 4, 2016, at 42, 44–48;
Michael Specter, The Gene Hackers, NEW YORKER, Nov. 16, 2015, at 52, 54; Nathaniel
Comfort, Can We Cure Genetic Diseases Without Slipping into Eugenics?, NATION (July
16, 2015), http://www.thenation.com/article/can-we-cure-genetic-diseases-without-slippinginto-eugenics/?print=1 [https://perma.cc/C9FL-2QT5]; Mike Feibus, CRISPR Gene
Editing Tool: Are We Ready to Play God?, USA TODAY (July 24, 2017, 9:00 AM),
https://www.usatoday.com/story/tech/columnist/2017/07/24/crispr-gene-editing-tool-weready-play-god/490144001/ [https://perma.cc/5WHE-X3W7].
12. See About Human Germline Gene Editing, CTR. FOR GENETICS & SOC’Y,
http://www.geneticsandsociety.org/article.php?id=8711 [https://perma.cc/6VC6-4N6N].
13. See Gary E. Marchant & Wendell Wallach, Coordinating Technology Governance,
ISSUES SCI. & TECH., Summer 2015, at 43, 43–45.
14. There have been two international summits on human genome editing to date. See
Press Release, Nat’l Acads. of Scis. Eng’g & Med., Second International Summit on
Human Genome Editing to Be Held in Hong Kong (May 8, 2018),
http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=05082018
[https://perma.cc/Z9V4-K7SY]. In addition, the National Academies of Science,
Engineering, and Medicine convened international scholarly meetings over several years
and issued an influential report in 2017. See generally NAT’L ACADS. OF SCIS., ENG’G, &
MED., HUMAN GENOME EDITING: SCIENCE, ETHICS, AND GOVERNANCE (2017)
[hereinafter NASEM, HUMAN GENOME EDITING] (“Recognizing both the promise and
concerns related to human genome editing, the National Academy of Sciences and the
National Academy of Medicine convened the Committee on Human Gene Editing:
Scientific, Medical, and Ethical Considerations to carry out the study that is documented
in this report.”). And the second issue of the CRISPR Journal featured a compendium of
position statements from around the world. See infra text accompanying note 82.
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The prospect of genetic modification, and the fears and hopes it
engendered, were first addressed in the 1970s in connection with the
Asilomar moratorium on recombinant DNA research.15 Discussion of
the ethical, legal, and social implications (“ELSI”) of genetic research
expanded in the 1990s when recombinant DNA research in humans
began to attempt correction of genetic defects and the Human
Genome Project began its work of finding and mapping all human
genes.16 Attention to the implications of gene-based treatment and
enhancement largely faded from view, however, after the mapping
project was completed and progress in clinical research slowed.
Despite the growth of multidisciplinarity in the biosciences,
collaboration between scientists and bioethics scholars has remained
challenging because of the rapid development of specialized
knowledge and the resultant information gaps and language barriers.
This means that ethical and policy thinking can at times lag behind
biotechnological developments or misunderstand or mischaracterize
them. 17 However, waiting to address the implications of a novel
biotechnology until it is more fully developed often means chasing
after what has rapidly become regarded as inevitable.18 Indeed, the
global response to Dr. He’s work may exemplify both the inherent

15. At the Asilomar Conference, the American scientific community voluntarily and
temporarily halted all recombinant DNA research until risks of harm were further
assessed and oversight mechanisms were created. See generally Paul Berg, Asilomar 1975:
DNA Modification Secured, 455 NATURE 290 (2008) (noting the successes of the
conference and considering whether an Asilomar-type conference could “help resolve
some of the controversies now confronting scientists and the public”); Michael Rogers,
The Pandora’s Box Congress, ROLLING STONE, June 19, 1975, at 36 (narrating the historic
conference through vignettes).
16. Eric D. Green, James D. Watson & Francis S. Collins, Twenty-Five Years of Big
Biology, 526 NATURE 29, 29–31 (2015).
17. When five percent of the federal funding for the Human Genome Project was set
aside for study of its ethical, legal, and social implications, bioethics scholarship went
mainstream. See Jean E. McEwen et al., The Ethical, Legal, and Social Implications
Program of the National Human Genome Research Institute: Reflections on an Ongoing
Experiment, 15 ANN. REV. GENOMICS & HUM. GENETICS 481, 481–82 (2014). Yet it also
became known for examining the potential of biotechnologies that had not yet come to
fruition and thus was sometimes regarded as standing in the way of science. Steven Pinker,
The
Moral
Imperative
for
Bioethics,
BOS. GLOBE
(Aug.
1,
2015),
https://www.bostonglobe.com/opinion/2015/07/31/the-moral-imperative-for-bioethics/JmEkoy
zlTAu9oQV76JrK9N/story.html [https://perma.cc/5AHD-HQNM (dark archive)].
18. Germline gene editing has been so characterized. See, e.g., Stephen S. Hall, Red
Line: Will We Control Our Genetic Destinies?, SCI. AM., Sept. 2016, at 54, 56–58; Antonio
Regalado, Engineering the Perfect Baby, MIT TECH. REV., May–June 2015, at 26, 32
[hereinafter Regalado, Engineering the Perfect Baby].
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limitations of guidance development and the failures of education and
enforcement.19
B.

Benefits, Harms, and Policy Tradeoffs

Two overarching policy questions that scientists, scholars, and
society began to address during the Asilomar moratorium have
reemerged as a result of CRISPR-Cas9: First, should our concerns be
focused only on safety and efficacy, or also on metaphysical matters
like the integrity of human genetic inheritance?20 And second, should
the debates and decisions be led by scientists who are experts in the
technology; by policymakers, bioethics scholars, and the general
public; or by the individuals and families affected by genetic
disorders, and their advocates? 21 In the current debate about
inheritable genetic modifications, more than a few prominent
scientists have agreed that science alone cannot answer ethics
questions; instead, they acknowledge the need for broad and robust

19. See discussion infra Part II; see also Antonio Regalado, Rogue Chinese CRISPR
Scientist Cited US Report as His Green Light, MIT TECH. REV. (Nov. 27, 2018),
https://www.technologyreview.com/s/612472/rogue-chinese-crispr-scientist-cited-us-reportas-his-green-light/ [https://perma.cc/EG4N-VPU3].
20. George J. Annas, Lori B. Andrews & Rosario Isasi, Protecting the Endangered
Human: Toward an International Treaty Prohibiting Cloning and Inheritable Alterations,
28 AM. J.L. & MED. 151, 151–53 (2002) [hereinafter Annas et al., Protecting the
Endangered Human]; George Annas, Scientists Should Not Edit Genomes of Human
Embryos, B.U. SCH. PUB. HEALTH (Apr. 30, 2015), https://www.bu.edu/sph/2015/04/30/
scientists-should-not-edit-genomes-of-human-embryos/ [https://perma.cc/U4NW-UXQM]
[hereinafter Annas, Human Embryos].
21. See, e.g., Ruha Benjamin, Interrogating Equity: A Disability Justice Approach to
Genetic Engineering, in INTERNATIONAL SUMMIT ON HUMAN GENE EDITING:
COMMISSIONED PAPERS 48, 48–51 (2015), www.nationalacademies.org/cs/groups/
pgasite/documents/webpage/pga_170455.pdf [https://perma.cc/MU37-9JRV]; Alta Charo,
The Legal/Regulatory Context, in INTERNATIONAL SUMMIT ON HUMAN GENE EDITING:
COMMISSIONED PAPERS, supra, at 13, 13–19; Erika Check Hayden, Tomorrow’s Children,
530 NATURE 402, 403–05 (2016); J. Benjamin Hurlbut, Limits of Responsibility: Genome
Editing, Asilomar, and the Politics of Deliberation, HASTINGS CTR. REP., Sept.–Oct. 2015,
at 11, 11–14; Eric T. Juengst, Crowdsourcing the Moral Limits of Human Gene Editing?,
HASTINGS CTR. REP., May–June 2017, at 15, 15–23; Daniel Sarewitz, Science Can’t Solve
It, 522 NATURE 413, 413–14 (2015); Sharon F. Terry, Societal Implications: The Role of
Advocacy Organizations, in INTERNATIONAL SUMMIT ON HUMAN GENE EDITING:
COMMISSIONED PAPERS, supra, at 36, 36–38; Charis Thompson, Governance, Regulation,
and Control: Public Participation, in INTERNATIONAL SUMMIT ON HUMAN GENE
EDITING: COMMISSIONED PAPERS, supra, at 44, 44–47; Antonio Regalado, Patients Favor
Changing the Genes of the Next Generation with CRISPR, MIT TECH. REV. (Dec. 2, 2015),
https://www.technologyreview.com/s/544141/patients-favor-changing-the-genes-of-the-nextgeneration-with-crispr/ [https://perma.cc/M6GD-6U2X].
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public debate.22 But whether that ethics debate should be framed as a
balance of the risks of harm against potential benefits only for
individuals and their progeny, or whether it should expand to address
the implications of multiple individual, inheritable changes for the
human species as a whole,23 is still at issue. At the same time, the
research is advancing rapidly and has already taken some
unprecedented directions.24
Scientists and the public alike recognize that potentially
astounding health benefits could follow from editing the human
germline. But there are real concerns as well. Introducing permanent
inheritable changes might introduce unintended errors that could
damage not only individual patient-subjects but also their future
offspring for generations. This concern arose when gene-transfer
research25 began in 1990.26 Gene transfer seeks to correct deleterious
genetic mutations by introducing multiple copies of nonmutated
versions of the responsible gene into the body.27 The principal risk of
harm comes from the possibility of “off-target effects”—that is, that
copies could insert into the wrong place in the genome, causing a
different and potentially deleterious mutation.28 That potential harm
is only to the individual so treated; however, it is common to monitor
22. See, e.g., Eric S. Lander, Brave New Genome, 373 NEW ENG. J. MED. 5, 5–8
(2015).
23. See Annas et al., Protecting the Endangered Human, supra note 20, at 153; Annas,
Human Embryos, supra note 20.
24. Chinese researchers in particular have surged ahead in both embryo research and
clinical applications, and He Jiankui was not the first to surprise the scientific community.
See discussion infra Part II.
25. Gene-transfer research was first misleadingly labeled “gene therapy.” See Nancy
M. P. King, Rewriting the “Points to Consider”: The Ethical Impact of Guidance Document
Language, 10 HUM. GENE THERAPY 133, 133 (1999). It has now been renamed “gene
augmentation” or “gene-addition” research to distinguish it from gene editing. See Thierry
VandenDriessche & Marinee K. Chuah, CRISPR-Cas9 Flexes Its Muscles: In Vivo Somatic
Gene Editing for Muscular Dystrophy, 24 MOLECULAR THERAPY 414, 414–16 (2016).
26. Coutts, supra note 5, at 63. The first human clinical gene-transfer experiment that
intended to develop a genetic treatment enrolled children with adenosine deaminase
deficiency, a severe combined immunodeficiency disorder. Francesca Ferrua &
Alessandro Aiuti, Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble
Babies to an Approved Drug, 28 HUM. GENE THERAPY 972, 972–74 (2017). The first
patient-subject in that experiment, Ashanti DeSilva, is still alive and well. See id. at 978.
27. See LEROY WALTERS & JULIE GAGE PALMER, THE ETHICS OF HUMAN GENE
THERAPY 18, 23, 26, 166–69 (1997); Nancy M. P. King, Accident & Desire: Inadvertent
Germline Effects in Clinical Research, HASTINGS CTR. REP., Mar.–Apr. 2003, at 23, 24
[hereinafter King, Accident & Desire]; VandenDriessch & Chuah, supra note 25.
28. The principal concern is that an off-target insertion will cause cancer. See, e.g.,
Salima Hacein-Bey-Abina et al., Efficacy of Gene Therapy for X-Linked Severe Combined
Immunodeficiency, 363 NEW ENG. J. MED. 355, 363 (2010).
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adult male patient-subjects in many gene-transfer clinical trials by
testing their semen to determine whether there are any potential
germline effects and to advise them against unprotected sex until
monitoring is completed.29
Gene editing, in contrast, does not flood the organism with new
copies of genes.30 Instead, it either removes mutated or damaged
sequences from genes, or removes them and replaces them with
undamaged versions. 31 One of the reasons that gene editing has
generated such scientific excitement is that it seems to be significantly
more precise, and potentially more accurate, as well as more effective
and more reliably permanent, than gene addition at its best.32
The key to gene editing is the creation of double-strand breaks in
the DNA double helix. Gene editing before CRISPR used ZFNs and
TALENs; these methods, which are still in use, required very precise
and painstaking construction of the proteins that break DNA, called
nucleases, to hit the right places where the DNA should be broken
(called cleavage sites).33 The discovery of CRISPR has rapidly led to
technologies that are much simpler and easier to use.34
29. The risk of germline effects from somatic cell gene-transfer interventions
historically arose only by accident. See, e.g., Katherine A. High, Gene Therapy for
Hemophilia: The Clot Thickens, 25 HUM. GENE THERAPY 915, 918 (2014). The semen of
some male gene-transfer research subjects was found to contain copies of the viral vector
used to insert the transgene into their somatic cells. Id. at 918 fig.3 (collecting wellpublicized incidents of such occurrence). This discovery led to monitoring of male patientsubjects; in gene-transfer trials using systemic administration of the vector-transgene
combination, semen is collected and tested to look for copies of the (deactivated) viral
vector used to carry the transgene into the body’s cells. Id. at 918. Persistence of vector has
always been temporary and has never appeared to include transgene or to affect sperm. Id.
This low risk of germline effects nonetheless raised concerns and has influenced study
design, altering the choice of vector in some gene-transfer protocols and the route of
administration of the vector-transgene combination in others, in order to reduce the
likelihood of germline transmission. See id. at 917–19; King, supra, at 23–26. In this
author’s opinion, concern about germline effects may have contributed to Jesse
Gelsinger’s death in a phase one gene-transfer protocol, because the FDA changed the
route of administration of the gene-transfer intervention from injection into the peripheral
circulation to injection into a vein leading directly to the liver, reasoning that the former
route was systemic and thus more likely to risk germline effects. Targeting the liver proved
more dangerous, however, as it provoked an overwhelming immune response that led to
Gelsinger’s death.
30. See Rodolphe Barrangou & Jennifer A. Doudna, Applications of CRISPR
Technologies in Research and Beyond, 34 NATURE BIOTECHNOLOGY 933, 933–36 (2016).
31. See id. at 934 (offering a short primer on CRISPR).
32. See generally id. (overviewing the wide variety of advantages CRISPR brings,
both generally and as applied to specific industries and research fields).
33. See id. at 933. For excellent discussions of all three biotechnologies, see generally
Thomas Gaj, Charles A. Gersbach & Carlos F. Barbas III, ZFN, TALEN, and
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CRISPR-Cas9 is the first and most popular of the new geneediting tools to be discovered and developed to date.35 It is stable,
simple, facile, affordable, specific, and highly versatile, able to target
any DNA sequence, to remove mutated sequences, and even to
replace them with nonmutated sequences.36 In comparison with the
imprecision of gene addition or augmentation, gene-editing
techniques appear to more precisely control the integration of new
genetic information, thereby decreasing (though not completely
eliminating) the possibility of harmful insertional mutagenesis and
other off-target effects.37 And CRISPR-Cas9 is so easy to use that kits
can be purchased online, enabling many scientists and students to

CRISPR/Cas9-Based Methods for Genome Engineering, 31 TRENDS BIOTECHNOLOGY
397 (2013); Rajat M. Gupta & Kiran Musunuru, Expanding the Genetic Editing Tool Kit:
ZFNs, TALENs, and CRISPR-Cas9, 124 J. CLINICAL INVESTIGATION 4154 (2014); and
Keener, supra note 10.
34. In 1993, Francisco Mojica identified multiple copies of palindromic repetitive
bases, interspaced with unique DNA spacers, in the DNA of a microbe. Eric S. Lander,
The Heroes of CRISPR, 164 CELL 18, 18 (2016). Its structural similarity to another
clustered repeat sequence with spacers that had previously been identified in a common
bacterium suggested biological significance across species. Yoshizumi Ishino et al.,
Nucleotide Sequence of the IAP Gene, Responsible for Alkaline Phosphatase Isozyme
Conversion in Escherichia Coli, and Identification of the Gene Product, 169 J.
BACTERIOLOGY 5429, 5432 (1987). These repetitive genetic sequences came to be known
as CRISPR. Mojica’s work outlining CRISPR’s likely function as an adaptive defense
mechanism, able to cut foreign DNA in order to cripple the ability of an invading virus to
replicate and damage the host, was published in early 2005. See Francisco J.M. Mojica et
al., Intervening Sequences of Regularly Spaced Prokaryotic Repeats Derive from Foreign
Genetic Elements, 60 J. MOLECULAR EVOLUTION 174, 180–81 (2005). Over the next
decade, CRISPR’s mechanism of action was examined and elucidated further. See Samuel
H. Sternberg & Jennifer A. Doudna, Expanding the Biologist’s Toolkit with CRISPRCas9, 58 MOLECULAR CELL 568, 568 (2015). It has now been developed into a highly
specific gene-editing tool.
35. See Le Cong et al., Multiplex Genome Engineering Using CRISPR/Cas Systems,
339 SCIENCE 819, 819–20, 822 (2013); Giedrius Gasiunas et al., Cas9-crRNA
Ribonucleoprotein Complex Mediates Specific DNA Cleavage for Adaptive Immunity in
Bacteria, 109 PROC. NAT’L ACAD. SCI. 2579, 2579, 2585 (2012); Martin Jinek et al., A
Programmable Dual-RNA-Guided Endonuclease in Adaptive Bacterial Immunity, 337
SCIENCE 816, 816, 820 (2012); Morgan L. Maeder & Charles A. Gersbach, GenomeEditing Technologies for Gene and Cell Therapy, 24 MOLECULAR BIOLOGY 430, 434–35
(2016).
36. See Jennifer A. Doudna & Emmanuelle Charpentier, The New Frontier of
Genome Engineering with CRISPR-Cas9, 346 SCIENCE 1077 passim (2014); Young-Il Jo et
al., CRISPR-Cas9 System as an Innovative Genetic Engineering Tool: Enhancements in
Sequence Specificity and Delivery Methods, 1856 BIOCHIMICA ET BIOPHYSICA ACTA 234,
234–36 (2015); Yue Mei et al., Recent Progress in CRISPR-Cas9 Technology, 43 J.
GENETICS & GENOMICS 63, 63–64, 71, 73 (2016).
37. Maeder & Gersbach, supra note 35, at 433–34.
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explore gene editing in almost any laboratory setting, or even at
home.38
Newer CRISPR models and related technologies are rapidly
being developed and tested. Such refinements are continually
underway to make gene-editing systems simpler, smaller, and more
precise.39 In particular, editing RNA (using Cas13 instead of Cas9)
has some advantages over editing DNA.40 Unlike DNA editing, RNA
editing is temporary.41 An RNA edit is therefore reversible if it goes
wrong in any way, and it can be applied to correct transient
conditions, such as damage caused by inflammation resulting from an
infection.42 RNA edits are also effective when cells are not actively
dividing, whereas DNA edits are linked to cell division. 43 This
difference means that RNA editing, unlike DNA editing, can be
applied to brain and muscle cells, as well as to cell types found in
other tissues. 44 Finally, RNA edits affect individual bases in the
sequences of base pairs that make up genes—and because single-base
mutations cause a number of human genetic diseases, RNA editing
could have the potential to treat those diseases precisely and
effectively (though not permanently).45
Another widely heralded improvement is base editing. Instead of
engineering double-strand breaks of DNA, that is, removing an entire
38. Park, supra note 11, at 45; see also infra text accompanying note 128. For more
information on biohacking in general, see Joe Brophy, God’s Name in Vein: Biohacker
Injects Himself with DNA Sequence Made from Bible and Koran Verses, THE SUN (Dec.
21, 2018, 12:58 AM), https://www.thesun.co.uk/news/8014880/biohacker-injects-dnasequence-bible-koran-verses/ [https://perma.cc/LD67-XQ3W].
39. See, e.g., Janice S. Chen et al., Enhanced Proofreading Governs CRISPR-Cas9
Targeting Accuracy, 550 NATURE 407, 407–10 (2017).
40. See, e.g., Jon Cohen, ‘Base Editors’ Open New Way to Fix Mutation: Novel
CRISPR-Derived Technologies Surgically Alter a Single DNA or RNA Base, 358 SCIENCE
432, 432–33 (2017); David B.T. Cox et al., RNA Editing with CRISPR-Cas13, 358 SCIENCE
1019, 1019–27 (2017).
41. Julia Belluz & Umair Irfan, 2 New CRISPR Tools Overcome the Scariest Parts of
Gene Editing, VOX (Oct. 25, 2017, 1:00 PM), https://www.vox.com/2017/10/25/
16527370/crispr-gene-editing-harvard-mit-broad [http://perma.cc/M3YD-U5ZH].
42. Id.
43. Id.
44. Id.
45. Id. But see Jon Cohen, Powerful CRISPR Cousin Accidentally Mutates RNA
While
Editing
DNA
Target,
SCIENCE
(Apr.
17,
2019,
4:10
PM),
https://www.sciencemag.org/news/2019/04/powerful-crispr-cousin-accidentally-mutates-rnawhile-editing-dna-target [https://perma.cc/56QW-CCRR] (“[T]he weaknesses of base
editors have become increasingly apparent, and a new study shows they can also
accidentally mutate the strands of RNA that help build proteins or perform other key
cellular tasks.”).
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step in the ladder of the double helix and then either allowing the
ends to reconnect without the missing step or inserting a repaired
replacement, base editing targets individual base pairs without
breaking the strand.46 Paired combinations of just four proteins make
up all human DNA, and thousands of human diseases are known to
be caused by mutations in just one base pair of matched proteins in
one gene. 47 For example, a mistake that puts one adenosinethymidine (“A-T”) pair where a guanine-cytosine (“G-C”) pair
should be causes half of known human genetic diseases.48 Therefore,
using base editing to change A-T pairs to G-C pairs could
permanently and precisely correct a great many deleterious
mutations.49 Base editing with an enzyme specially synthesized for this
purpose is being studied in cell cultures and in small animal models,50
and has been pronounced successful in human embryos with Marfan
syndrome in a paper by Chinese researchers.51
Is it possible for ethics and policy to keep up with the breakneck
pace of this science? Maybe; but it sure ain’t easy.
II. A BRIEF HISTORY OF CRISPR NEWS AND POLICY
Gene editing made headlines in March 2015 when a group of
senior scientists and scholars led by Jennifer Doudna published
recommendations arising from a California conference that invited
comparison with the 1970s Asilomar moratorium on recombinant
DNA research. 52 They recommended a moratorium on “germline
genome modification for clinical application in humans, while
societal, environmental, and ethical implications of such activity are
46. Belluz & Irfan, supra note 41; see also Nicole M. Gaudelli et al., Programmable
Base Editing of A-T to G-C in Genomic DNA Without DNA Cleavage, 551 NATURE 464,
464–65 (2017); Alexis C. Komor et al., Programmable Editing of a Target Base in Genomic
DNA Without Double-Stranded DNA Cleavage, 533 NATURE 420, 420–24 (2016); Brian S.
Plosky, CRISPR-Mediated Base Editing Without DNA Double-Strand Breaks, 62
MOLECULAR CELL 477, 477–78 (2016).
47. Belluz & Irfan, supra note 41.
48. Gaudelli et al., supra note 46, at 464.
49. Id.
50. See, e.g., Yuanwu Ma et al., Letter to the Editor, Highly Efficient and Precise Base
Editing by Engineered dCas9-Guide tRNA Adenosine Deaminase in Rats, 4 CELL
DISCOVERY 1, 1–3 (2018).
51. Yantinq Zeng et al., Correction of the Marfan Syndrome Pathogenic FBN1
Mutation by Base Editing in Human Cells and Heterozygous Embryos, 26 MOLECULAR
THERAPY 2631, 2631–32 (2018).
52. David Baltimore, A Prudent Path Forward for Genomic Engineering and
Germline Gene Modification, 348 SCIENCE 36, 36–38 (2015).
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discussed among scientific and governmental organizations.”53 They
called for discussion of information and education about the science
and its implications, asked that a “globally representative group” be
convened to make policy recommendations, and sought support for
“transparent research to evaluate . . . genome engineering
technology” to examine “its potential applications for germline gene
therapy.”54 At around the same time, the International Society for
Stem Cell Research (“ISSCR”) issued a similar position statement.55
And a week later, another group of scientists published a sterner call
for a moratorium accompanied by international dialogue “to assess
whether, and under what circumstances—if any—future research
involving genetic modification of human germ cells should take
place.”56
Almost immediately thereafter, Protein & Cell published the
results of a Chinese experiment attempting CRISPR-Cas9
modification of nonviable human embryos with the apparent aim of
determining the feasibility of moving to therapeutic genome editing in
viable human embryos.57 The Chinese researchers’ findings of both
off-target insertions and mosaicism—that is, successful editing of
some but not all of the embryos’ cells, resulting in a “mosaic” pattern
of edited and unedited cells—were troubling; so was their failure to
conduct more basic research first.58
At the end of April 2015, the National Institutes of Health
(“NIH”) announced that it would not fund any use of gene-editing
technology in human embryos.59 And in the summer and fall of 2015,
several additional position statements appeared.60 A joint statement
by the American Society of Gene and Cell Therapy (“ASGCT”) and

53. Id. at 37.
54. Id.
55. Statement, Int’l Soc’y for Stem Cell Research, The ISSCR Statement on Human
Germline Genome Modification (Mar. 19, 2015), http://www.isscr.org/docs/defaultsource/guidelines/isscr-statement-on-human-germline-genome-modification.pdf?sfvrsn=2
[https://perma.cc/TPC9-5XV6].
56. Edward Lanphier et al., Don’t Edit the Human Germ Line, 519 NATURE 410, 411
(2015).
57. Puping Liang et al., CRISPR/Cas9-Mediated Gene Editing in Human
Tripronuclear Zygotes, 6 PROTEIN & CELL 363, 363 (2015).
58. Id. at 366.
59. Statement, Nat’l Insts. of Health, Statement on NIH Funding of Research Using
Gene-Editing Technologies in Human Embryos (Apr. 29, 2015) (on file with the North
Carolina Law Review).
60. See infra text accompanying notes 61–63.
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the Japan Society of Gene Therapy (“JSGT”) 61 joined the more
cautious side of the discussion. Echoing the initial statement from
Doudna’s group, statements by the Hinxton Group 62 and the
International Bioethics Committee of the United Nations 63 raised
cautions but did not call for a halt on gene-editing research that could
affect the human germline.
The Doudna group’s call for global attention came to fruition in
early December 2015, with the First International Summit on Human
Genome Editing.64 On December 3, the summit issued a statement
that closely tracked the Doudna group’s recommendations: basic and
preclinical research should go forward, somatic cell gene editing
should go forward in clinical application, germline gene editing
should not head toward the clinic, and an ongoing international forum
should be created to continue discussion of the ELSI of gene
editing.65
That forum, the Committee on Human Gene Editing of the
National Academies, was created immediately after the summit. The
committee held international meetings examining the state of the
science, the potential for clinical benefit, the risks of harm, and the
ELSI of human gene-editing technologies.66 It also considered and
assessed existing standards, oversight mechanisms, and safeguards

61. Theodore Friedmann et al., ASGCT and JSGT Joint Position Statement on
Human Genomic Editing, 23 MOLECULAR THERAPY 1282, 1282 (2015).
62. Statement, Hinxton Grp., Statement on Genome Editing Technologies and
Human Germline Genetic Modification (Sept. 10, 2015) (on file with the North Carolina
Law Review).
63. See generally Int’l Bioethics Comm., UNESCO, Rep. of the Int’l Bioethics Comm.
on Updating its Reflection on the Human Genome and Human Rights, U.N. Doc.
SHS/YES/IBC-22/15/2 REV.2 (Oct. 2, 2015) (discussing various ethical challenges posed
by gene editing of the human genome without calling for an outright ban on the practice in
the future).
64. See STEVEN OLSON, NAT’L ACADS. OF SCIS., ENG’G, & MED., INTERNATIONAL
SUMMIT ON HUMAN GENE EDITING: A GLOBAL DISCUSSION 6–7 (2015). For a sampling
of the broad range of views included in the summit, see generally INTERNATIONAL
SUMMIT ON HUMAN GENE EDITING: COMMISSIONED PAPERS, supra note 21.
65. Statement, Nat’l Acads. of Scis. Eng’g & Med., On Human Gene Editing:
International Summit Statement (Dec. 3, 2015), http://www.nap.edu/21913
[https://perma.cc/PFE6-Y9X2]; see also Sara Reardon, Global Summit Reveals Divergent
Views on Human Gene Editing, 528 NATURE 173, 173 (2015). See generally
INTERNATIONAL SUMMIT ON HUMAN GENE EDITING: COMMISSIONED PAPERS, supra
note 21 (presenting various issues on which the summit took a position).
66. Consensus Study, NAT’L ACADEMIES SCI., ENGINEERING & MED.,
http://www.nationalacademies.org/gene-editing/consensus-study/index.htm [http://perma.cc/
5HFT-AEYC].
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worldwide.67 Its final report, Human Genome Editing: Science, Ethics,
and Governance, appeared in February 2017.68 The report’s widely
anticipated recommendations have generally been interpreted as
opening the doors to the future a little wider, in two respects. First,
the report recommends limiting human clinical trials of somatic gene
editing to prevention and treatment applications “at this time” and
calls for public discussion and policy debate on enhancement
applications, thus setting the stage for enhancement research in the
future. 69 Second, it recommends permitting human germline gene
editing, but only for compelling purposes—that is, when there are no
reasonable alternatives and the intervention is intended to prevent or
treat serious disease or disability.70 The report thus even more clearly
sets the stage for germline interventions in the not-too-distant future,
depending on what counts as a reasonable alternative. 71 It also
requires rigorous and comprehensive oversight and long-term
multigenerational follow-up and recommends transnational
cooperation and ongoing public reassessment.72
The summer of 2017 saw a number of additional developments.
The American College of Medical Genetics and Genomics published
a points-to-consider document on genome editing in clinical
genetics;73 it concluded that “genome editing in the human embryo is
premature” and strongly encouraged “broad public debate,”
continued research to resolve technological problems, and resisting
pressure for premature clinical application.74 Shortly thereafter, the
American Society of Human Genetics led a large group of genetics
and medical organizations that published a comprehensive joint
position statement on human-germline genome editing, which divided
the ethical issues into those arising from its failure and those arising
from its success,75 and concluded that “at this time,” germline gene
editing intended for human pregnancy is “inappropriate,” but in vitro

67. Id.
68. NASEM, HUMAN GENOME EDITING, supra note 14.
69. Id. at 133–39.
70. Id. at 134.
71. Id. at 134–35.
72. Id.
73. ACMG Bd. of Dirs., Am. Coll. of Med. Genetics & Genomics, Genome Editing in
Clinical Genetics: Points to Consider—A Statement of the American College of Medical
Genetics and Genomics, 19 GENETICS MED. 723, 723–24 (2017).
74. Id. at 724.
75. Kelly E. Ormond et al., Human Germline Genome Editing, 101 AM. J. HUM.
GENETICS 167, 167–76 (2017).
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human germline-editing research should go forward and should be
publicly funded. 76 Echoing the Human Gene Editing report, the
position statement further argued that human clinical applications of
germline editing should not proceed unless there is a compelling
medical and ethical rationale, good preclinical evidence, and a
transparent public process.77
Finally, the first human-embryo editing in the United States
came to light in the summer of 2017. Oregon Health Sciences
University’s (“OHSU”) Shoukrat Mitalipov and his team edited
viable human zygotes, which they created using healthy oocytes and
sperm containing a genetic mutation that causes hypertrophic
cardiomyopathy, and which thus had a 50/50 chance of carrying the
mutation.78 They edited these zygotes with a CRISPR-Cas9 package
that included a normal synthetic copy of the mutated gene so that the
mutation could be replaced with the synthetic copy.79 Their published
results claimed a high degree of success with few off-target effects and
almost no mosaicism, but did contain a surprising wrinkle: the normal
gene was not the synthetic version but a copy of the normal version
found in the oocyte genome.80 These results have been questioned as
improbable.81 It seems likely that a definitive answer will emerge only
76. Id. at 172–73.
77. Id. at 173–74.
78. Hong Ma et al., Correction of a Pathogenic Gene Mutation in Human Embryos,
548 NATURE 413, 413–16 (2017).
79. Id.
80. Id. at 416–18. Not surprisingly, there was considerable discussion triggered by this
revelation in the science-oriented popular press about the ethics of gene editing human
embryos, with some particularly skeptical. See, e.g., Eliza Barclay, Scientists Successfully
Used CRISPR to Fix a Mutation that Causes Disease. This Is Huge., VOX (Aug. 2, 2017,
3:50 PM), https://www.vox.com/science-and-health/2017/8/2/16083300/crispr-heart-disease
[http://perma.cc/R24J-EHT9]; Sharon Begley, U.S. Scientists Edit Genome of Human
Embryo, but Cast Doubt on Possibility of ‘Designer Babies,’ STAT (Aug. 2, 2017),
www.statnews.com/2017/08/02/crispr-designer-babies/?utm [http://perma.cc/L8M3-ZKSP];
Jessica Berg, Editing Human Embryos with CRISPR Is Moving Ahead—Now’s the Time
to Work Out the Ethics, CONVERSATION (July 28, 2017, 11:40 AM),
https://theconversation.com/editing-human-embryos-with-crispr-is-moving-ahead-nows-thetime-to-work-out-the-ethics-81732 [http://perma.cc/PC4W-99G3]; Emily Mullin, Gene
Editing Study in Human Embryos Points Toward Clinical Trials, MIT TECH. REV. (Aug.
2, 2017), https://www.technologyreview.com/s/608482/gene-editing-study-in-human-embryospoints-toward-clinical-trials/ [http://perma.cc/R24J-EHT9]; Kelly Servick, First US-Based
Group to Edit Human Embryos Brings Practice Closer to Clinic, SCIENCE (Aug. 2, 2017,
1:00 PM), https://www.sciencemag.org/news/2017/08/first-us-based-group-edit-human-embryosbrings-practice-closer-clinic [http://perma.cc/7PEP-3CQ5].
81. Skeptical researchers argue that the editing process may simply have deleted a
portion of DNA that included the mutation, and that Mitalipov’s team detected the one
remaining normal maternal gene, not two copies of it, but the team has responded that
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if there is continued research by other teams attempting to duplicate
OHSU’s results.
All things considered, it should be clear by now that human
genome editing is of enormous social and policy interest, but keeping
track of the position papers, reports, guidances, and commentaries is
as much of a challenge as keeping up with the science. There is even a
journal devoted entirely to CRISPR, and its second issue contains a
useful compilation and review of the many statements relating to the
ethical and policy implications of the science—but that list appeared
in print in early 201882 and already needs updating. Most notably, the
Second International Summit on Human Genome Editing took place
in Hong Kong on November 27–29, 2018. 83 It included a hastily
rearranged session featuring He Jiankui, whose claim of having
brought gene-edited twins to live birth had shocked the world just
days before.84 The repercussions of Dr. He’s work are still being felt,
and new and amended policy and guidance documents are being
published and prepared.85
In brief, Dr. He, a Chinese national who studied in the United
States while developing his embryo-editing plans, claims to have
edited the genomes of twin girls at fertilization in order to increase
their resistance to HIV infection.86 Dr. He has also claimed that
another pregnancy resulting from his research was underway as of

two copies of the maternal gene have been detected and that as-yet-unpublished work
confirms that gene repair preferentially seeks the healthy maternal gene. Ewen Callaway,
Did CRISPR Really Fix a Genetic Mutation in These Human Embryos?, NATURE (Aug. 8,
2018), https://www.nature.com/articles/d41586-018-05915-2 [http://perma.cc/Q9BU-4KPX].
82. Carolyn Brokowski, Do CRISPR Germline Ethics Statements Cut It?, 1 CRISPR J.
115, 115–23 (2018).
83. The summit website includes agenda information, slide presentations, videos, and
a concluding statement. Second International Summit on Human Genome Editing, NAT’L
ACADEMIES SCI., ENGINEERING & MED., http://www.nationalacademies.org/geneediting/2nd_summit/ [http://perma.cc/RYX5-GJAS].
84. Regalado, Chinese Scientists, supra note 3.
85. For example, eight European specialty societies have published a statement in
response to Dr. He’s work. Hildegard Büning et al., Consensus Statement of European
Societies of Gene and Cell Therapy on the Reported Birth of Genome-Edited Babies in
China, 29 HUM. GENE THERAPY 1337, 1337–38 (2018). Other work is still underway. See,
e.g., Sharon Begley, After ‘CRISPR Babies,’ International Medical Leaders Aim to Tighten
Gnome Editing Guidelines, STAT (Jan. 24, 2019), https://www.statnews.com/2019/01/
24/crispr-babies-show-need-for-more-specific-rules/?utm_content=buffer3335a&utm_medium=
social&utm_source=twitter&utm_campaign=twitter_organic [https://perma.cc/BMV7-HFVT].
86. Marilynn Marchione, Chinese Researcher Claims First Gene-Edited Babies,
ASSOCIATED PRESS (Nov. 26, 2018), https://www.apnews.com/4997bb7aa36c45449b488e19
ac83e86d [http://perma.cc/6NXR-GE76].
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late November 2018.87 These claims were recently substantiated by
Chinese authorities,88 but there is still no peer-reviewed publication of
Dr. He’s research at the time of this writing, and scientists who
reviewed the slides he presented at the summit in Hong Kong are
skeptical about his data.89 Dr. He presented his claims to the world in
a YouTube video,90 and reporter Antonio Regalado broke the story
of his work in the MIT Technology Review shortly before the summit
began.91
Apparently, Dr. He recruited couples in which the man has HIV
infection and the woman does not and told them that he was
conducting HIV vaccine research.92 Dr. He collected sperm and ova
from the man and woman, washed the sperm before fertilizing the
ovum with it—which is well known to render transmission of HIV to
the embryo virtually impossible—and then sought to edit out a gene
that plays a role in helping HIV enter cells, ostensibly to increase the
resulting child’s resistance to HIV infection. 93 Crucially, Dr. He
admitted that the edit was not successful in one of the embryos, and it
is unclear whether it was completely or even partially successful in the
other.94 In addition, it is probable that disabling or deleting the gene
in question decreases resistance to other, more common infections.95
87. Ashley P. Taylor, Second CRISPR-Modified Pregnancy May Be Underway,
SCIENTIST (Nov. 28, 2018), https://www.the-scientist.com/news-opinion/second-crisprmodified-pregnancy-may-be-underway-65151 [http://perma.cc/V8BG-MQPV].
88. Phoebe Zhang, China Confirms Birth of Gene-Edited Babies, Blames Scientist He
Jiankui for Breaking Rules, S. CHINA MORNING POST (Feb. 4, 2019, 11:47 AM),
https://www.scmp.com/news/china/science/article/2182964/china-confirms-gene-edited-babiesblames-scientist-he-jiankui [https://perma.cc/TDE7-DA9K].
89. See Katarina Zimmer, CRISPR Scientists Slam Methods Used on Gene-Edited
Babies, SCIENTIST (Dec. 4, 2018), https://www.the-scientist.com/news-opinion/crisprscientists-slam-methods-used-on-gene-edited-babies--65167 [http://perma.cc/Z3VY-MVQK];
see also Amy Dockser Marcus, Scientists Skeptical About Gene-Edited Baby Experiment,
WALL ST. J. (Dec. 12, 2018, 7:00 AM), https://www.wsj.com/articles/gene-edited-babiesexperiment-raises-concerns-11544616000 [http://perma.cc/K6FR-WMBT]. See generally
Sean P. Ryder, #CRISPRbabies: Notes on a Scandal, 1 CRISPR J. 355, 355–57 (2018)
(noting that there are enough uncertainties about Dr. He’s work to “raise clear scientific
objections”); Ed Yong, The CRISPR Baby Scandal Gets Worse by the Day, ATLANTIC
(Dec. 3, 2018), https://www.theatlantic.com/science/archive/2018/12/15-worrying-thingsabout-crispr-babies-scandal/577234/ [http://perma.cc/F3XT-WH9P] (detailing fifteen
“worrying things” about Dr. He’s research).
90. The He Lab, supra note 3.
91. See Regalado, Chinese Scientists, supra note 3.
92. See Marchione, supra note 86.
93. Regalado, Chinese Scientists, supra note 3; see also Marchione, supra note 86.
94. See Marchione, supra note 86; Zimmer, supra note 89; see also Ryder, supra note
89, at 355.
95. See Marchione, supra note 86; Zimmer, supra note 89.
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Moreover, the embryos were not infected or diseased in any way;
such an edit constitutes prevention, or enhancement, rather than
treatment (and of course, there are many other, far less invasive ways
to prevent HIV infection).96 Thus, bringing these edited embryos to
live birth violates every guidance document and every ethical and
policy standard in place around the world. Questions also abound
about the validity of regulatory approvals Dr. He claims to have
obtained and the clarity, completeness, and accuracy of the consent
form signed by the couple.97 The Chinese government has condemned
Dr. He’s work and suspended all his activities.98
And yet, Dr. He has managed to claim the spotlight and rekindle
fierce debate about clinical applications of CRISPR.99 Scientific and
policy developments therefore seem to be leading inexorably—and
pretty swiftly—toward an expansive research portfolio and clinical
applications of gene editing. So now it is time to ask: Why not?
III. WHAT ARE THE ETHICAL AND POLICY ISSUES IN GENE
EDITING?
Editing the human germline might be an accidental attribute of a
genuinely successful gene-editing treatment, or it might be gene
editing’s true goal. Does the difference matter? Well, yes, if it points
toward enhancement applications and thereby complicates
consequent policy implications. Questions of oversight and
governance, access and cost, and even more basically, whether and if
so how tightly future clinical applications of the technology should be
controlled, all need to address how far it is okay to go.

96. Yong, supra note 89; see also Catherine Offord, Claim of First Gene-Edited Babies
Triggers Investigation, SCIENTIST (Nov. 26, 2018), https://www.the-scientist.com/newsopinion/claim-of-first-gene-edited-babies-triggers-investigation-65139 [http://perma.cc/5RTPK6F4].
97. See Yong, supra note 89; see also Xiaomei Zhai et al., Chinese Bioethicists
Respond to the Case of He Jiankui, HASTINGS CTR. (Feb. 7, 2019),
https://www.thehastingscenter.org/chinese-bioethicists-respond-case-jiankui/ [https://perma.cc/
8VT3-3428].
98. Offord, supra note 96; Antonio Regalado, The Chinese Scientist Who Claims He
Made CRISPR Babies Is Under Investigation, MIT TECH. REV. (Nov. 26, 2018),
https://www.technologyreview.com/s/612466/the-chinese-scientist-who-claims-he-made-crisprbabies-has-been-suspended-without-pay/ [http://perma.cc/X6CE-C2F3].
99. See supra notes 84–85 and accompanying text.
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A. Is Germline Genome Editing Necessary, or Just Way Cool?
Avoiding disease by means of genetic intervention requires
knowing which genes are involved in disease causation. Once genes
have been identified, treatments are generally sought for affected
individuals and designed to be applied to somatic cells—that is, to
edit the DNA in the affected cells of the individual’s body. Somatic
cell genetic correction has been the goal of human genetic
manipulation since its beginning.100 Correction of the genetic defects
in all or most of the affected somatic cells of an individual with a
known genetic disorder would, by definition, be a treatment—even a
cure—for that person.101 Gene-editing research designed to correct
genetic defects in the somatic cells of adults or children is less likely to
pose a risk of inadvertent germline effects than is gene-addition
research.102 Thus, it is far less problematic, as long as standards of
safety and efficacy are met.103
A representative gene-editing example is Sangamo Therapeutics’
trial of an in vivo gene-editing intervention for Hunter syndrome, or
mucopolysaccharidosis type II, using ZFNs. 104 The first patient100. See generally WALTERS & PALMER, supra note 27, at 17–59 (describing the
science and ethics of somatic cell gene therapy, which affects the research subject or
patient but not future generations, and which still represents the only type of genetic
research intervention or genetic treatment permissible in humans).
101. See id.
102. Sharon Begley, They’re Going to CRISPR People. What Could Possibly Go
Wrong?, STAT (June 23, 2016), https://www.statnews.com/2016/06/23/crispr-humanspenn-clinical-trial/ [http://perma.cc/DUD7-XBBT].
103. See, e.g., Kaiwen Ivy Liu et al., A Chemical-Inducible CRISPR-Cas9 System for
Rapid Control of Gene Editing, 12 NATURE CHEMICAL BIOLOGY 980, 980–82 (2016); see
also Begley, supra note 102. Nonetheless, it matters whether the gene-editing tool used
simply snips out the defective sequence and allows the DNA to rejoin without it—a
process known as nonhomologous end joining—or whether the defective sequence is
replaced with a nonmutated sequence, which is known as homologous recombination or
homology directed repair. Nonhomologous end joining is now known to be less precise
than homology-directed repair; it also raises the interesting possibility that merely deleting
the mutated sequence could also delete potentially beneficial genetic information and thus
be as harmful as it is helpful. See, e.g., Moises Velasquez-Manoff, Opinion, The Upside of
Bad Genes, N.Y. TIMES (June 17, 2017), https://www.nytimes.com/2017/06/17/
opinion/sunday/crispr-upside-of-bad-genes.html [http://perma.cc/67WS-EVUW].
104. Jocelyn Kaiser, A Human Has Been Injected with Gene-Editing Tools to Cure His
Disabling Disease. Here’s What You Need to Know, SCIENCE (Nov. 15, 2017),
http://www.sciencemag.org/news/2017/11/human-has-been-injected-gene-editing-tools-cure-hisdisabling-disease-here-s-what-you [http://perma.cc/PE4J-PLYX]. More recently, University of
Pennsylvania researchers began a trial using CRISPR-Cas9 to alter the T cells of adult
patient-subjects with cancer. See Shawna Williams, Two Patients Treated with CRISPRed
Cells in Immunotherapy Trial, SCIENTIST (Apr. 16, 2019), https://www.the-scientist.com/
news-opinion/two-patients-treated-with-crispred-cells-in-immunotherapy-trial-65744
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subject, an adult man, was enrolled in November 2017, and no safety
concerns appear to have emerged after enrollment of several more
adult patient-subjects in this dose-escalation trial.105 However, the
results have been disappointing,106 as is often the case the first time a
new potential treatment is studied in human patient-subjects.
Importantly, the experimental gene-editing intervention in this
trial cannot cross the blood-brain barrier,107 so it cannot actually edit
DNA in all the affected somatic cells. Because of the difficulty of
reaching and effectively correcting all the affected cells in many
genetic disorders, studying possible gene-editing treatments in
affected patient-subjects is of great importance, but somatic cell gene
editing in adults, and even in children, may not be as effective as
interventions timed to prevent development of genetic disorders or to
halt damage at an early stage. Treating an already-born person with
somatic cell gene editing may not be perfectly effective if it is not
possible to edit most or all of the affected DNA. If only some of the
affected cells in the body are successfully edited, this results in
mosaicism—a mosaic mixture of affected and corrected cells.
Depending on the nature of the condition and the degree of
correction, some mosaicism may be enough to effectively treat the
condition, and in other cases, the effect may not be sufficient. In
contrast, editing an early embryo can improve correction and avoid
mosaicism, because the embryo has fewer cells needing correction,
and all of the cells in an early embryo are rapidly dividing and can
thus perpetuate the correction throughout development. Therefore,
early intervention seems a logically superior route, as long as the risk
of genetic disease is known.
Once a couple has given birth to a child diagnosed with a genetic
disorder, the child’s parents and their close relatives can learn more
about their own relevant genetic makeup and can use various means
[https://perma.cc/M53N-3NW2]. Both the treatment-oriented headline and the very
preliminary public announcement about this research demonstrate current overexcitement
about CRISPR’s potential.
105. Kaiser, supra note 104; Marilynn Marchione, Early Results Boost Hopes for
Historic
Gene
Editing
Attempt,
ASSOCIATED PRESS
(Sept.
5,
2018),
https://www.apnews.com/2543a04b925c443b9ad3987f4209e68e [http://perma.cc/6MQY-YXAW];
Andrew McConaghie, No Safety Concerns So Far in Sangamo’s Groundbreaking GeneEditing Trial, PHARMAPHORUM (Feb. 7, 2018), https://pharmaphorum.com/news/no-safetyconcerns-far-sangamos-groundbreaking-gene-editing-trial/ [http://perma.cc/SW4U-RRAH].
106. Ron Leuty, Why This East Bay Biotech Company Shed Half Its Value, S.F. BUS.
TIMES (Feb. 7, 2019), https://www.bizjournals.com/sanfrancisco/news/2019/02/07/sangamosgmo-genome-editing-mps-hurler-hunter.html [https://perma.cc/4C65-A3L7 (dark archive)].
107. Kaiser, supra note 104.
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to prevent the birth of additional affected children. Interestingly,
current debates about germline gene editing tend to skip over
discussion of some of those means. For example, long before the
beginnings of the Human Genome Project, Ashkenazi Jewish
communities worldwide began collating family histories to try to
identify individuals whose offspring might be at risk of being affected
by Tay-Sachs disease, a devastating neurodegenerative genetic
disorder more common in persons with Ashkenazi Jewish ancestry
than in the general population.108 Couples seeking to marry might be
counseled to find another partner, to forgo procreation, or to adopt.
As a result, the global incidence of Tay-Sachs disease has decreased
substantially. 109 Scientific advances have made even more options
available to carrier couples, most notably including IVF to create a
small number of embryos, PGD to test them for Tay-Sachs mutations,
and selecting unaffected embryos to implant and bring to term.110
Preventing germline transmission of genetic disease through the
selection of healthy embryos is widely available in affluent countries.
Assisted reproduction technology (“ART”) has expanded rapidly in
recent decades, and IVF with PGD has become almost standard for
those in need of reproductive health services, especially couples
affected by genetic disorders who wish to give birth to a genetically
related but unaffected child.111 However, IVF and PGD are relatively
costly services, with prices ranging from four to six figures, depending
on location and insurance coverage.112 In the United States, these
procedures are largely the province of the private sector, are not
comprehensively regulated, and are far from always paid for by

108. The Jewish Genetic Disease Consortium maintains a web resource on Tay-Sachs
Disease that includes extensive information on the disorder, carrier screening for couples,
and options for couples who screen positive. Tay-Sachs Disease, JEWISH GENETIC
DISEASE CONSORTIUM, https://www.jewishgeneticdiseases.org/diseases/tay-sachs-disease/
[http://perma.cc/H3CW-X6W9].
109. Marvin R. Natowicz & Elizabeth M. Prence, Heterozygote Screening for TaySachs Disease: Past Successes and Future Challenges, 8 CURRENT OPINION PEDIATRICS
625, 627 (1996); Roberto Rozenberg & Lygia da Veiga Pereira, The Frequency of TaySachs Disease-Causing Mutations in the Brazilian Jewish Population Justifies a Carrier
Screening Program, 119 SAO PAULO MED. J. 146, 146 (2001).
110. Learning About Tay-Sachs Disease, NAT’L HUM. GENOME RES. INST.,
https://www.genome.gov/10001220/learning-about-taysachs-disease/ [http://perma.cc/43S2H29Y]; see also Natowicz & Prence, supra note 109, at 626.
111. Robert Klitzman, How Much Is a Child Worth? Providers’ and Patients’ Views
and Responses Concerning Ethical and Policy Challenges in Paying for ART, 12 PLOS
ONE, e0171939, Feb. 16, 2017, at 1, 2.
112. Id. at 1–2.
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private health insurance or included in government-funded health
care.
It is usually possible—not always, but almost always—to use IVF
and PGD to select an unaffected embryo instead of editing an
affected embryo. Regardless of whether the goal is to select an
unaffected embryo or to edit one that is affected, it is necessary to use
IVF to create one embryo or several, and then to use PGD to
determine whether any are affected by the genetic disorder of
concern (or are carriers). Selecting and implanting an unaffected
embryo is thus a key alternative to editing an affected embryo. If
editing an individual at a later stage—as an adult, a child, or even a
fetus—is not enough, either because of mosaicism or because later
editing cannot reverse early damage that occurs before the editing
process is undertaken, then it might seem logical to regard embryo
editing as nothing other than an alternative to embryo selection. The
earlier the editing process begins in development, the more likely it is
that all of the body’s cells will be corrected, including those of the
(immature) gametes. This effectively makes germline editing a “side
effect” of effective treatment.
The gene-editing debate has thus reintroduced an important
question113: If IVF and PGD are commonly used to select disease-free
offspring, are there any good reasons to pursue gene editing of
embryos (or of gametes114) aside from the rare instances when no
unaffected embryo can be selected because all of a couple’s embryos
will be affected? Most commentators have answered no;115 some have
113. Terence R. Flotte, Therapeutic Germ Line Alteration: Has CRISPR-Cas9
Technology Forced the Question?, 26 HUM. GENE THERAPY 245, 245 (2015).
114. Hall, supra note 18; Regalado, Engineering the Perfect Baby, supra note 18, at 27–
30; see also George Church, Compelling Reasons for Repairing Human Germlines, 377
NEW ENG. J. MED. 1909, 1910 (2017); Antonio Regalado, A New Way to Reproduce, MIT
TECH. REV., Sept.–Oct. 2017, at 33, 35–38 [hereinafter Regalado, A New Way to
Reproduce].
115. See, e.g., Hampton, supra note 5, at 547–48; see also, e.g., Friedmann et al., supra
note 61, at 1282; Elisabeth Hildt, Human Germline Interventions—Think First,
FRONTIERS GENETICS, May 2016, at 1, 1–3; Lander, supra note 22, at 5–7; supra text
accompanying notes 66–72 (addressing the National Academies of Science, Engineering,
and Medicine’s cautious opposition to germline gene editing). In responding “no” to this
question, numerous other scientists and bioethics scholars have condemned He Jiankui’s
gene-editing experiments as both unnecessary and potentially dangerous. See supra notes
86–99 and accompanying text. Further, Francis Collins, Director of the National Institutes
of Health, added his censure in a strongly worded statement. Statement, Francis S. Collins,
Dir., Nat’l Insts. of Health, Statement on Claim of First Gene-Edited Babies by Chinese
Researcher (Nov. 28, 2018), https://www.nih.gov/about-nih/who-we-are/nih-director/
statements/statement-claim-first-gene-edited-babies-chinese-researcher [http://perma.cc/

97 N.C. L. REV. 1051 (2019)

2019]

GENE-EDITING RESEARCH

1075

emphasized caution, without ruling out the future possibility;116 and a
few have responded, “Of course; why not?”117
Robust and reliable understanding of whether editing very early
embryos or gametes can provide complete correction and target
specificity is still in very short supply. Given our limited knowledge of
the relationships among genes and between genes and the
environment, genetic alteration of embryos or gametes might have
completely unexpected consequences, which can be avoided simply
by selecting an unaffected embryo. It thus seems only prudent to limit
human clinical applications of gene editing to instances of true
necessity, when an unaffected embryo cannot be selected. Recently,
however, noted medical scientist George Daley has argued that many
couples with low fertility may not be able to use IVF to create enough
embryos to identify one that is unaffected to implant and bring to
term.118 This could potentially expand the “necessary” application of
embryo editing considerably.119
But these are all safety questions. Some additional questions that
should be asked may also highlight assumptions on which the whole
field of ART is based. These questions touch on some potentially
broader issues of social policy and ethics: Should every couple be able
to pursue giving birth to children who are genetically related to both
S28Y-QG4F]; see also Jon Cohen, Francis Collins Ponders Fallout from CRISPR Baby
Study, SCIENCE (Nov. 30, 2018, 11:50 AM), https://www.sciencemag.org/news/2018/11/
epic-scientific-misadventure-nih-head-francis-collins-ponders-fallout-crispr-baby-study
[http://perma.cc/Q3GG-UYW6].
116. See, e.g., Dana Carroll, A Perspective on the State of Genome Editing, 24
MOLECULAR THERAPY 412, 412–13 (2016); Flotte, supra note 113, at 245; Raheleh
Heidari, David M. Shaw & Bernice Elger, CRISPR and the Rebirth of Synthetic Biology,
23 SCI. ENGINEERING ETHICS 354, 355–57 (2016); Matthew H. Porteus & Christina T.
Dann, Commentary, Genome Editing of the Germline: Broadening the Discussion, 23
MOLECULAR THERAPY 980, 981–82 (2015); Jeremy Sugarman, Ethics and Germline Gene
Editing, 16 EMBO REPS. 1, 1 (2015); Xiamoei Zhai, Vincent Ng & Reidar Lie, No Ethical
Divide Between China and the West in Human Embryo Research, 16 DEVELOPING
WORLD BIOETHICS 116, 117, 119 (2016).
117. See, e.g., Church, supra note 114, at 1910–11; Hall, supra note 18, at 57–58; Julian
Savulescu et al., The Moral Imperative to Continue Gene Editing Research on Human
Embryos, 7 PROTEIN CELL 476, 477 (2015); James Gallagher, Embryo Engineering a
Moral Duty, Says Top Scientist, BBC NEWS (May 13, 2015), www.bbc.com/news/ukpolitics-32633510 [https://perma.cc/K5F5-DUBZ]; Pinker, supra note 17. Notably, George
Church was the only scientist quoted as not condemning He Jiankui for his human
genome-editing CRISPR experiment. See Marchione, supra note 86; Yong, supra note 89.
118. George Q. Daley, Robin Lovell-Badge & Julie Staffann, Perspective, After the
Storm—A Responsible Path for Genome Editing, 380 NEW ENG. J. MED. 897, 898–99
(2019).
119. Id.
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parents? Should that effort overshadow adoption or the use of
donated gametes? Should couples who have religious or personal
objections to discarding any embryo be able to create only a single
embryo, and correct it if needed, rather than creating more than one
in order to identify and select one that is unaffected?
And finally, and most central here, is it reasonable to regard the
complexities and uncertainties of creating germline effects as
acceptable side effects of embryo editing under the circumstances, in
comparison to its potential benefits, even in instances of true need?
How can germline effects be adequately studied in future generations
from the perspectives of both science and ethics? How should
genetically altered offspring be regarded? Are they lifelong research
subjects? For how many generations?120 Could editing the germline
alter the human genetic inheritance? What does that mean? Should
we do so? What sort of policy process should be in place to address
these questions? Is it possible to reach international agreement on
whether to permit, and if so, how to regulate human germline
alteration?121
Although the germline effects of editing embryos, zygotes, or
even gametes were initially posited as a side effect of effective
treatment, it may ultimately be impossible to distinguish between
germline alteration as a side effect and as a goal. If widespread use of
IVF and PGD alone could remove most genetic diseases from the
human genetic inheritance, then shouldn’t embryo editing be reserved
for disorders that can be removed from the human genetic
inheritance only by choosing not to procreate or by editing embryos
or gametes? Perhaps because the same considerations and concerns
exist about germline gene editing regardless of its status as side effect
or goal, few efforts are made to preserve a distinction. Instead, most
popular arguments in favor of embryo editing start and end with the
goal of eradicating devastating genetic diseases forever.122
120. Friedmann et al., supra note 61, at 1282.
121. WALTERS & PALMER, supra note 27, at 90–91; Mark S. Frankel & Audrey R.
Chapman, Facing Inheritable Genetic Modifications, 292 SCIENCE 1303, 1303 (2001);
Juengst, supra note 21, at 15, 19; see discussion infra Section III.D.
122. Survey research very much depends on exactly how questions are asked, and to
whom. See, e.g., CARY FUNK & MEG HEFFERON, PEW RESEARCH CTR., PUBLIC VIEWS
OF GENE EDITING FOR BABIES DEPEND ON HOW IT WOULD BE USED 2–3 (2018). It is
quite understandable that when people are asked about using gene editing to eliminate
their own diseases from the population, they will find it easier to imagine themselves as
healthy than to imagine that their parents selected an unaffected embryo instead of using
gene editing on theirs. See Mullin, supra note 80.
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When analysis of the ethical appropriateness of embryo editing
equates editing with selection or fails to compare, consider, or even
mention embryo selection, this increases the perceived acceptability
of gene editing.123 It also helps to promote what some have argued is
the real goal of embryo editing: genetic enhancement.124 Arguments
in favor of genetic enhancement are further assisted by the
conceptual fuzziness of the line between treatment and enhancement.
B.

Appropriate Research Targets: Treatment or Enhancement?

Whether germline genetic alteration should be limited to
treatment for genetic disorders or should encompass enhancements as
well is yet another debate that has been going on for many decades.125
Discussion of the similarities and differences among prevention,
treatment, and enhancement is a debate that is older and broader
than genetics, even though it has considerable significance in genetic
intervention. Consider just two examples: vaccines enhance immune
system function in order to prevent infection; erythropoetin is a
treatment used to restore red blood cell production after cancer
chemotherapy causes anemia, but it is also used to increase the
blood’s oxygen-carrying capacity in order to prevent altitude sickness
or enhance aerobic efficiency in healthy individuals. Many other such
examples exist, including administering human growth hormone
(“HGH”) as a treatment for children who have lower than normal
HGH levels, while also giving HGH to uncomplicatedly short
children with normal HGH levels to enhance the height they
inherited from their parents. Many such “off label” uses of
interventions developed as treatments have been proposed and
undertaken in the history of medicine and medical research.126
123. See, e.g., Cohen, supra note 115.
124. See, e.g., Robert Sparrow, A Not-So-New Eugenics: Harris and Savulescu on
Human Enhancement, HASTINGS CTR. REP., Jan.–Feb. 2011, at 32, 32–33; see also Eric T.
Juengst et al., Is Enhancement the Price of Prevention in Human Genome Editing?, 1
CRISPR J. 1, 1–2 (2018).
125. See WALTERS & PALMER, supra note 27, at 110–11.
126. The history of human gene-transfer research reveals numerous hopes for genetic
enhancement, including but not limited to discussions about the feasibility of extending
treatment uses of gene-transfer interventions to enhancement purposes. For example,
could a gene-transfer intervention for cancer-caused cachexia be used to increase muscle
mass in athletes (which, if done, would constitute difficult-to-detect “gene doping”)?
Could delivering additional corrected copies of the mutated gene responsible for PraderWilli syndrome, a genetic disorder that includes insatiable appetite, to healthy overweight
people suppress their appetites and result in weight loss? Might industry be interested in
helping to develop a gene-transfer intervention to spur rapid regrowth of hair after
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Examples like these demonstrate the difficulty of cleanly
distinguishing between enhancement and treatment. The terms
themselves are ambiguous and context dependent; treatment in one
setting is enhancement in another. Moreover, as treatment
interventions become more common, what is regarded as a condition
in need of treatment is highly likely to expand into territory
previously regarded as reserved for enhancement only, in the same
way that the indications for use of an approved treatment virtually
always expand over time.127
Discussion of the ethical and policy debates about human
enhancement, from everyday examples to the extremes of the antiaging movement and transhumanism, is far beyond the scope of this
Article. Several aspects of genetic enhancement nonetheless deserve
mention.
First, assessing and balancing the risks of harm and potential
benefits in enhancement research poses a particular challenge. It is far
easier, and much less morally problematic, to weigh potential benefits
and risks of harm in human research when the potential benefits are
understood as a return to normal functioning—a treatment—than
when the research subject is a healthy patient for whom “better than
normal” is the goal. Despite this difficulty, biohackers have sought to
enhance themselves.128 Enhancing human embryos should certainly
be given far more serious consideration.
But what if genetic enhancement is just at the far end of a
continuum that represents the generally praiseworthy, or at least not
automatically contemptible, desire to better ourselves? Humans

chemotherapy so that it could also be used off-label for correction of male pattern
baldness? All of these speculative possibilities have been discussed in meetings of the NIH
Recombinant DNA Advisory Committee.
127. ERIC T. JUENGST & DANIEL MOSELEY, STANFORD ENCYCLOPEDIA OF
PHILOSOPHY, HUMAN ENHANCEMENT 12 (Edward N. Zalta et al. eds., Spring 2016 ed.
2016), https://plato.stanford.edu/entries/enhancement/ [https://perma.cc/7T6J-5FEX]; Juengst,
supra note 21, at 21; Eric T. Juengst, Can Enhancement Be Distinguished from Prevention
in Genetic Medicine?, 22 J. MED. & PHIL. 125, 126 (1997); Tristan Keys et al., Faith in
Science: Professional and Public Discourse on Regenerative Medicine, in AFTER THE
GENOME: A LANGUAGE FOR OUR BIOTECHNOLOGICAL FUTURE 11, 32–33 (Michael J.
Hyde & James A. Herrick eds., 2013).
128. See, e.g., Josiah Zayner, The First Attempt at Human CRISPR Gene Editing, SCI.,
ART, BEAUTY (Oct. 13, 2017), http://www.josiahzayner.com/2017/10/the-first-human-toattempt-crispr-gene.html [https://perma.cc/8RM5-AXM6]; Sarah Zhang, A Biohacker
Regrets Publicly Injecting Himself with CRISPR, ATLANTIC (Feb. 20, 2018),
https://www.theatlantic.com/science/archive/2018/02/biohacking-stunts-crispr/553511/
[https://perma.cc/W86Z-VM2Z].
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already enhance themselves and their children in a wide variety of
relatively modest ways: eyeglasses and laser surgery for myopia,
education and Ritalin for academic achievement, meditation and even
controlled administration of hallucinogens for moral enhancement,
and caloric restriction for life extension. Inheritable genetic
enhancements may hold the potential to change the balance of
characteristics in a society more pervasively and permanently than
other enhancement technologies currently available to individuals
and families. Individual choices to ensure that one’s children and
grandchildren are blond haired and blue-eyed, taller than average,
more trusting and compassionate, possessing higher IQs, or needing
less sleep potentially have a wide range of possible consequences
across societies. Yet all parents seek to secure advantages for their
children and pass them on across generations through the acquisition
and inheritance of wealth, education, employment opportunities and
experiences, contacts and connections, and other forms of social
capital. Are genetic enhancements different in kind from other
enhancements, or do they differ only in degree of precision,
penetrance, and irreversibility?
Many of the enhancements just described would not be regarded
as advantageous if everyone had them. Being tall, or blond haired and
blue-eyed, matters little if everyone is tall, or blond haired and blueeyed; these characteristics, and others that matter only if you have
them and others do not, are, in economic or philosophical terms,
positional goods.129 Some enhancements, in contrast, may continue to
be desirable nevertheless, at least within limits. For example, more
education or greater intelligence, more stamina, less need for sleep,
and staying healthier longer may all confer advantages over
individuals who lack these characteristics, but each enhancement may
still have value if everyone shares them; they are, philosophically
speaking, intrinsic goods. 130 Even in circumstances where incomerelated disparities will surely limit access to any and all genetic
enhancements, whether for individuals alone or also for their
progeny, it is worth considering what kinds of enhancements are even
worthy of consideration in a society that seeks to be both free and
fair.

129. FRED HIRSCH, THE SOCIAL LIMITS TO GROWTH 27 (rev. ed. 2005).
130. MICHAEL J. ZIMMERMAN, STANFORD ENCYCLOPEDIA OF PHILOSOPHY,
INTRINSIC VS. EXTRINSIC VALUE 5–8 (Edward N. Zalta et al. eds., Spring 2015 ed. 2015),
https://plato.stanford.edu/entries/value-intrinsic-extrinsic/ [https://perma.cc/VBG5-3PLY].
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Finally, even the most highly valued of intrinsic goods has a place
on a continuum from enhancements that manipulate normal species
functioning in minor ways, such as bringing short people up to the
species norm or improving eyesight beyond 20/20 vision, to those that
change normal species functioning more profoundly, such as tripling
the human lifespan or enabling humans to photosynthesize in order to
counter a shrinking food supply on an overheating planet. Inheritable
genetic modifications, now potentially made much easier by gene
editing, may be difficult to undo. Thus, even if genetic enhancement is
currently no more than a philosopher’s dream, contemplating the
inheritable changes that could in the future be wrought by human
germline gene editing may add at least a modicum of urgency to
ongoing ethical and policy deliberations about human enhancement.
We need to worry about this because it simply may not be possible to
avoid embryo enhancement if embryo editing goes forward.
C.

Oversight and Governance, Domestic and Global

That gene editing provides an unparalleled opportunity to
address significant questions about governance of new technologies,
appropriate oversight, and issues of justice, both domestic and global,
seems an understatement. That we are very far from being able to
capitalize on that opportunity seems equally obvious. The reasons are
legion: international scientific competition, a proliferation of
regulatory and oversight mechanisms replete with gaps and overlaps,
historical precedents like the “Wild West” of ART in the United
States, and the accessibility and affordability of do-it-yourself
CRISPR kits for at-home biohacking are just a few of the
contributors to the patchwork picture.131
131. See generally Marianne J. Legato et al., Editing the Human Genome: Progress and
Controversies, 1 GENDER & GENOME 4, 5–7 (2016) (recounting a roundtable discussion
on the progress of human gene editing and the reasons it is controversial). In addition, the
European Union’s recent determination that gene-edited organisms should be regarded as
genetically modified organisms from a regulatory standpoint has added confusion and
consternation to the mix. See Press Release, Court of Justice of the European Union,
Organisms Obtained by Mutagenesis Are GMOs and Are, in Principle, Subject to the
Obligations Laid Down by the GMO Directive (July 25, 2018), https://curia.europa.eu/
jcms/upload/docs/application/pdf/2018-07/cp180111en.pdf [https://perma.cc/72JD-GHPN].
Finally, organisms obtained by mutagenesis qualify as genetically modified and are
therefore subject to the GMO Directive’s obligations. Id.; see also Rodolphe Barrangou,
CRISPR Craziness: A Response to the EU Court Ruling, 1 CRISPR J. 251, 251 (2018);
Press Release, Court of Justice of the European Union, supra. One important, agreedupon but largely nonregulatory limitation on human embryo research—the so-called
fourteen-day rule—is applied widely but differently across national boundaries and plays a

97 N.C. L. REV. 1051 (2019)

2019]

GENE-EDITING RESEARCH

1081

To address this kind of complexity, which is not at all
unprecedented, Marchant and Wallace have suggested applying a
model called a “governance coordinating committee,” which can
make use of a “soft law” approach to novel biotechnologies by
serving a managerial “honest broker” function. 132 Is there a path
forward for establishing a governance coordination committee for
gene editing? Well, the summary statement from the organizers of the
Second International Summit on Human Genome Editing
calls for an ongoing international forum to foster broad public
dialogue, develop strategies for increasing equitable access to
meet the needs of underserved populations, speed the
development of regulatory science, provide a clearinghouse for
information about governance options, contribute to the
development of common regulatory standards, and enhance
coordination of research and clinical applications through an
international registry of planned and ongoing experiments.133
In addition, consider that the NIH has recently decided to yet
again revise and reduce the role of the Recombinant DNA Advisory
Committee (“RAC”) in the oversight of human gene-transfer
research, having concluded that gene-transfer research no longer
needs the scrutiny that should be afforded to novel biotechnologies.
As part of this revision, “to use the RAC as a public forum to advise
on issues associated with emerging biotechnologies, the RAC’s
charter will be modified to change the committee’s focus from

fundamental role in gene editing and related research. Insoo Hyun, Amy Wilkerson &
Josephine Johnston, Human-Embryo Research: Revisit the 14-Day Rule, 533 NATURE 169,
170 (2016).
132. Marchant & Wallach, supra note 13, at 46, 48 (“Emerging technologies require a
coordinated, holistic, and nimble approach, while not sacrificing diligence in overseeing
discernible dangers. . . . It would be an illusion to think that a GCC, or any other body,
could resolve these problems altogether. However, through advice, influence, and building
rapport among stakeholders, a GCC could play a key role in modulating the development
and deployment of new technologies. Today, no single institution is positioned to play
such a role.”).
133. Statement, Organizing Comm. of the Second Int’l Summit on Human Genome
Editing, On Human Genome Editing II (Nov. 29, 2018) [hereinafter Organizing
Committee Statement], http://www8.nationalacademies.org/onpinews/newsitem.aspx?
RecordID=11282018b [https://perma.cc/7WU2-DB2R]; see also Statement, Marcia
McNutt, President, Nat’l Acad. of Scis., and Victor J. Dzau, President, Nat’l Acad. of
Med., Statement on the Second International Summit on Human Genome Editing (Nov.
29, 2018) [hereinafter Presidents’ Statement], http://www8.nationalacademies.org/
onpinews/newsitem.aspx?RecordID=11282018c [https://perma.cc/DD25-95HH].
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research solely involving recombinant or synthetic nucleic acids to
emerging biotechnologies research.”134
If the RAC is actually reformulated to provide a public forum
that can advise broadly on scientific, safety, and ethical issues arising
in research on emerging biotechnologies, perhaps there is some hope
that it could continue to listen, deliberate, and influence the progress
of gene-editing research and related biotechnologies. That would be
desirable. It remains to be seen whether the NIH truly intends to
make this change; however, its director, Francis Collins, has
referenced it in his response to the He Jiankui scandal.135 It is far from
clear at the time of this writing what this model could really
accomplish.136 Even so, another proponent of responsible research
progress instead of moratoria in this socially and politically sensitive
area has also called for a comprehensive regulatory roadmap that
would incorporate a wide variety of guidelines, controls, and
checkpoints.137
D. A Moratorium?
Notably, in mid-March an international group of genome
scientists and bioethics scholars published an article in Nature calling
for a moratorium on “heritable genome editing.”138 An accompanying
editorial echoed the need for better regulation and broader
discussion,139 and the same issue published letters from NIH and the
National Academies supporting a moratorium.140
The moratorium call is detailed, addressing the need to improve
the efficiency of IVF and PGD as potentially preferable to clinical
genome editing, endorsing the continuation of basic genome-editing
134. NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid
Molecules, 83 Fed. Reg. 41,082, 41,083 (Aug. 17, 2018); see also Francis S. Collins & Scott
Gottlieb, The Next Phase of Human Gene-Therapy Oversight, 379 NEW ENG. J. MED.
1393, 1395 (2018) (“The NIH envisions using the RAC as an advisory board on today’s
emerging biotechnologies, such as gene editing, synthetic biology, and neurotechnology,
while harnessing the attributes that have long ensured its transparency.”).
135. See Cohen, supra note 115; see also Organizing Committee Statement, supra note
133; Presidents’ Statement, supra note 133.
136. Nancy M. P. King, RAC Oversight of Gene Transfer Research: A Model Worth
Extending?, 30 J.L. MED. & ETHICS 381, 386 (2002).
137. R. Alta Charo, Rogues and Regulations of Germline Editing, 380 NEW ENG. J.
MED. 976, 976 (2019).
138. Eric Lander et al., Adopt a Moratorium on Heritable Genome Editing, 567
NATURE 165, 165–68 (2019).
139. Editorial, Set Rules for Genome Editing, 567 NATURE 145, 145 (2019).
140. Correspondence, 567 NATURE 175, 175 (2019).
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research, and positing the global moratorium on clinical genome
editing as voluntary and temporary. Not surprisingly, however, it was
immediately controversial, with prominent scientists and scholars
supporting both sides of the question for a wide range of reasons.141
As at least two international expert groups,142 with some members
already clearly in both “slow down” and “move ahead” camps, have
pledged to work together to define terms, discuss scientific and ethical
issues, and set standards in germline genome-editing research, the
controversy over global governance and research policy is sure to
remain significant.
E.

Access and Cost

Cost and access have been important concerns for all treatment
technologies for as long as paying for health care has been an issue.
Both domestically and on a global scale, new biotechnologies often
come with immense price tags. 143 Gene-transfer, cell-based, and
regenerative-medicine interventions are, generally speaking, very
expensive; some efforts are being made to reduce costs through scaleup and standardization,144 but the success of such efforts is uncertain.

141. Jon Cohen, New Call to Ban Gene-Edited Babies Divides Biologists, SCIENCE
(Mar. 13, 2019, 2:00 PM), https://www.sciencemag.org/news/2019/03/new-call-ban-geneedited-babies-divides-biologists [https://perma.cc/9KSX-XJLA]. And on April 24, in a
letter sent to Alex Azar, United States Secretary of Health and Human Services, sixty-two
scientists and bioethics scholars strongly supported a moratorium. See Gene Therapy
Leaders Urge Global Moratorium on Germline Editing, GENETIC ENGINEERING &
BIOTECHNOLOGY NEWS (Apr. 24, 2019), https://www.genengnews.com/topics/genomeediting/gene-therapy-leaders-urge-global-moratorium-on-germline-editing/ [https://perma.cc/
E9VA-ZS96].
142. There is a new WHO expert advisory committee to develop governance and
oversight standards for human genome editing. WHO Expert Advisory Committee on
Developing Global Standards for Governance and Oversight of Human Genome Editing,
WORLD HEALTH ORG.,
https://www.who.int/ethics/topics/human-genome-editing/
committee-members/en/ [https://perma.cc/J3FD-CUX8]. There is also an international
commission, formed by the National Academies of Science and Medicine and the United
Kingdom Royal Society. See Correspondence, supra note 140, at 175.
143. E.g., Nancy M. P. King & Christine E. Bishop, New Treatments for Serious
Conditions: Ethical Implications, 24 GENE THERAPY 534, 536 (2017); Damien Garde, The
Cure for ‘Bubble Boy’ Disease Will Cost $665,000, STAT (Aug. 3, 2016),
https://www.statnews.com/2016/08/03/gene-therapy-price-gsk/ [https://perma.cc/L8EX-6PKS];
Meghana Keshavan, We May Soon Have Our First $1 Million Drug. Who Will Pay for It?
And How?, STAT (Oct. 13, 2017), https://www.statnews.com/2017/10/13/gene-therapypricing/?utm [https://perma.cc/T5JF-QFCH].
144. Joshua G. Hunsberger, Thomas Shupe & Anthony Atala, An Industry-Driven
Roadmap for Manufacturing in Regenerative Medicine, 7 STEM CELLS TRANSLATIONAL
MED. 564, 564–68 (2018).
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It is possible that the speed and simplicity of CRISPR-Cas9 and
other gene-editing tools may help to reduce gene editing’s ultimate
cost. Even significant cost reductions will not necessarily improve the
affordability of future treatments, however, particularly for patients
in resource-poor countries, unless gene editing proves far more
curative and considerably cheaper than currently available
treatments, thus making it feasible to ensure global accessibility.
Countries that cannot afford to provide basic health care for the
people residing within their borders are unlikely to provide novel
biotechnologies, even at low cost. Countries that—like the United
States—choose to condition access to health care on the ability to pay
for it, with exceptions for only some of those with the least resources
and the greatest need, are unlikely to remove or lower that barrier for
particular new technologies, no matter how promising.
This is only to say that the cost problem in health care is
pervasive; gene editing will simply be another new and expensive
biotechnology. But because gene editing of embryos must necessarily
be integrated into existing ART systems, which are already financially
out of reach for many, disparities of access will surely be exacerbated
unless our thinking about payment for such services changes
profoundly.
And yet, it must be acknowledged that the issue of fair access to
costly biotechnologies is a question of distributive justice that is
confined to the rather small and circumscribed realm of rescue
medicine. There are other, much broader distributive justice
questions that should also be considered. We should ask: How should
we distribute not only fair access to novel biotechnological treatments
but also to preventive services and also to the support services that
are often so necessary when treatments are not cures? How should we
fairly apportion funding for health-related research between the
development of novel biotechnologies and the search for effective
prevention? Should we focus instead on identifying, addressing, and
ameliorating the many social factors that give rise to health disparities
but that have proven more challenging—and much less exciting—
than pursuing cutting-edge science? 145 Should we even consider
thinking beyond health, to engage more seriously in collective
discussion about all the things that make up a good life, and about

145. REBECCA DRESSER, WHEN SCIENCE OFFERS SALVATION 47 (2001).
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what societies should do to make the lives of the people who live in
them better?146
IV. CAN POLICY SHAPE SCIENCE?
Somatic cell gene editing is not new, although CRISPR-Cas9, its
relatives, and the recent development of even newer and potentially
more precise techniques, like base editing, have made it far easier.
However, the editing of early embryos and gametes is necessarily
controversial. There is still agreement that clinical research involving
human embryos intended for reproduction must wait until much more
is known, but calls for complete avoidance of germline gene editing
are increasingly in the minority.
A. Is Germline Editing the Future?
The question whether deliberate germline gene editing should
ever be permitted is a question about the nature of the need. IVF
combined with PGD is a safe and effective already-existing
alternative to gene editing of embryos or gametes in all but the few
circumstances where a genetic disorder will necessarily appear in all
of the embryos a couple can produce. Yet there are would-be parents
who might prefer editing a single embryo over creating and testing
multiple embryos, selecting and implanting one or two unaffected
embryos, and discarding the rest.147 And there are other would-be
parents with a range of different reasons for seeking gene editing.148
146. Juengst, supra note 21, at 19. See generally MADISON POWERS & RUTH FADEN,
SOCIAL JUSTICE: THE MORAL FOUNDATIONS OF PUBLIC HEALTH AND HEALTH POLICY
(2008) (proposing that health is only one of six essential dimensions of well-being to which
all people deserve access).
147. Nonetheless, what philosophers refer to as the “nonidentity problem”—that is,
that selecting an unaffected embryo means choosing a different potential person, whereas
editing an embryo means treating the same potential person—may be a distinction that is
more illusory than meaningful. Interview with Janet Malek, Assoc. Professor, Baylor Coll.
of Med. (Oct. 19, 2018).
148. See Daley et al., supra note 118, at 897–99 (addressing the needs of couples with
low fertility). For instance, there are would-be fathers with genetic disorders who would
choose to have their spermatogonial stem cells genetically altered and reimplanted into
their testes so that they can reproduce “naturally.” See Church, supra note 114, at 1909–11.
And there are same-sex couples who would choose to create bipaternal or bimaternal
embryos, should that technology become available. See Zhi-Kun Li et al., Generation of
Bimaternal and Bipaternal Mice from Hypomethylated ESCs with Imprinting Region
Deletions, 23 CELL STEM CELL 665, 665 (2018). It is noteworthy that the He Jiankui
scandal has not deterred some researchers from studying similar preventive interventions.
See Antonio Regalado, Despite CRISPR Baby Controversy, Harvard University Will Begin
Gene-Editing Sperm, MIT TECH. REV. (Nov. 29, 2018), https://www.technologyreview.com/
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When editing, rather than selection, is chosen or necessary,
germline alteration is then a side effect of editing embryos, zygotes, or
gametes in order to ensure that the intervention is completely
effective with little or no possibility of mosaicism. But affecting the
germline is also a goal in itself, accomplished by either embryo
selection or embryo editing. IVF, PGD, and embryo selection already
work to eliminate deleterious conditions from the human germline,
without gene editing’s uncertain and unknown effects on future
generations. Yet there is no groundswell of enthusiasm for making
these standard technologies more widely available. The scientific
excitement
that
accompanies
genetic
manipulation
risks
overwhelming the ability of professionals and the public to place
these novel biotechnologies in perspective.149
As a result, it is highly likely that over time, more and more
embryo editing could come to be regarded as necessary, along with its
germline effects, whether inadvertent or desired. And only editing
can create (and perpetuate) enhancements.
B.

Is Enhancement Inevitable?

The prospect of genetic enhancement is far more feasible with
gene editing than it has ever been with gene addition. The simple
existence of the technology has given rise to an imaginative fervor
that so far has outpaced serious discussion about what enhancement
means and what its consequences might be—despite the greatly
expanded problems of assessing safety and even of predicting the
meaning of efficacy when enhancement rather than correction is at
issue.150
s/612494/despite-crispr-baby-controversy-harvard-university-will-begin-gene-editing-sperm/
[https://perma.cc/2KEA-CXFW].
149. There are undoubtedly ambitious scientists and entrepreneurs who are inspired
rather than deterred by Dr. He’s experience. See Antonio Regalado, The DIY Designer
Baby Project Funded with Bitcoin, MIT TECH. REV. (Feb. 1, 2019),
https://www.technologyreview.com/s/612838/the-transhumanist-diy-designer-baby-fundedwith-bitcoin/ [https://perma.cc/S4FV-WUMQ]. And though beyond the scope of this
Article, editing gametes is definitely regarded by the scientific community as a viable
strategy to be studied, and one highly reputable scientist, George Daley, Dean of Harvard
Medical School, supports continuing research looking toward clinical applications, even
after Dr. He. See Regalado, A New Way to Reproduce, supra note 114, at 35.
150. The regulatory requirements for research with human subjects require a
reasonable balance between risks of harm and potential benefits. But as discussion of Dr.
He’s research demonstrates, when seeking to enhance a healthy human, it is at best
somewhat challenging to assess the potential benefits of making someone “better than
normal” and compare those elusive benefits to the risks of harm. See Rebecca Dresser,
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Addressing the problem of unequal access to costly
biotechnologies barely dents the ethical issues raised by this
challenging future possibility. Gene editing represents a major
scientific leap forward, rekindling public excitement about the
possibility of significant amelioration of genetic disorders in the
foreseeable future. Yes, it will take quite some time before many
human clinical gene-editing trials using CRISPR-Cas9 are underway,
but clinical translation seems likely to move more quickly than it has
for other novel biotechnologies. After all, research in healthy human
embryos was approved in two countries just a year after the first
publication of gene-editing research in tripronuclear human embryos
in China.151 And the controversy over He Jiankui’s work is likely to
continue for some time.152
C.

Sticking to the Basics: A Proposal

Despite the push toward clinical applications of human embryo
editing, it matters a great deal whether the translational pathway is
expected to follow a straight line or not. It seems likely that geneticmodification research in human embryos will continue and expand,
but basic and proof-of-principle research may be far more vital than
speeding toward the clinic. Gene-editing research using human
embryos to gain basic knowledge of embryonic development and
infertility is currently underway. Researchers received approval early
in 2016 to use CRISPR-Cas9 in healthy donated embryos in the
United Kingdom and in Sweden; by September, National Public
Radio announced that the Swedish team had started their work.153
Genetic Modification of Preimplantation Embryos: Toward Adequate Human Research
Policies, 82 MILBANK Q. 195, 207, 209 (2004); Yong, supra note 89.
151. See Michelle Taylor, Japan Joins List of Countries that Allow Gene Editing in
Human Embryos, LABORATORY EQUIPMENT (Oct. 5, 2018, 2:06 PM),
https://www.laboratoryequipment.com/news/2018/10/japan-joins-list-countries-allow-geneediting-human-embryos [https://perma.cc/Z8HM-YURE].
152. In recent news identified for this Article, Dr. He continued to defend his research
and stated that he was seeking publication of his data. Luke W. Vrotsos, Chinese
Researcher Who Said He Gene-Edited Babies Breaks Week of Silence, Vows to Defend
Work, HARV. CRIMSON (Dec. 7, 2018), https://www.thecrimson.com/article/2018/12/
7/harvard-profs-react-to-human-gene-edit/ [https://perma.cc/7XMC-XG9R]. But cf. Henry
T. Greely, He Jiankui, Embryo Editing, CCR5, the London Patient, and Jumping to
Conclusions, STAT (Apr. 15, 2019), https://www.statnews.com/2019/04/15/jiankui-embryoediting-ccr5/ [https://perma.cc/QE3G-KKQS] (“Not only was He ethically wrong in doing
this work, but its scientific basis was even weaker than generally recognized.”).
153. Ewen Callaway, Embryo Editing Gets Green Light, 530 NATURE 18, 18 (2016);
Ewen Callaway, Embryo-Editing Research Gathers Momentum, 532 NATURE 289, 289
(2016); Park, supra note 11, at 45; Rob Stein, Breaking Taboo, Swedish Scientist Seeks to
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Since then, researchers in the United Kingdom and elsewhere have
made significant contributions to basic knowledge of embryo
development and disease modeling. 154 Recently, an expert panel
convened by the Japanese Ministry of Education, Culture, Sports,
Science, and Technology drafted guidelines recommending gene
editing of human embryos for basic science research. 155 And a
developmental biologist in the United States is using CRISPR to test
the efficacy of editing deleterious mutations like retinitis pigmentosa
out of human embryos in very early stages of development.156
Although basic embryo research using CRISPR might seem like
nothing other than the first step on the pathway of clinical translation,
it should instead be considered a goal in itself. CRISPR was
discovered and developed because scientific curiosity led to scientific
excitement about the ability to understand, refine, and manipulate a
newly identified biological ability. The basic embryo research that
CRISPR makes possible seeks to improve scientific understanding of
human growth and development in ways that may not lead directly to
clinical applications but that may have far greater capacity to improve
the health of many in the long run. Renewed attention to basic
principles of careful and deliberate knowledge-generating research
can do a lot to slow the race to the clinic and help to ensure that what
ultimately succeeds in moving from “bench to bedside” is safe and
effective, because more is known about how and why it works.157
Edit DNA of Healthy Human Embryos, NPR (Sept. 22, 2016, 5:07 AM),
http://www.npr.org/sections/health-shots/2016/09/22/494591738/breaking-taboo-swedishscientist-seeks-to-edit-dna-of-healthy-human-embryos [https://perma.cc/7T6J-5FEX].
154. See, e.g., Norah M. E. Fogarty et al., Genome Editing Reveals a Role for OCT4 in
Human Embryogenesis, 550 NATURE 67, 67 (2017); Heidi Ledford, CRISPR Used to Peer
into Human Embryos’ First Days, NATURE (Sept. 20, 2017), https://www.nature.com/
news/crispr-used-to-peer-into-human-embryos-first-days-1.22646 [https://perma.cc/EU5KJ5GN].
155. David Cyranoski, Japan Set to Allow Gene Editing in Human Embryos, NATURE
(Oct. 3, 2018), https://www.nature.com/articles/d41586-018-06847-7 [https://perma.cc/
FXG4-ZTST].
156. Rob Stein, New U.S. Experiments Aim to Create Gene-Edited Human Embryos,
NPR (Feb. 1, 2019, 5:42 PM), https://www.npr.org/2019/02/01/690822745/u-s-scientistsresearching-gene-editing-in-human-embryos [https://perma.cc/XJ75-3Z5F].
157. JONATHAN KIMMELMAN, GENE TRANSFER AND THE ETHICS OF FIRST-INHUMAN RESEARCH: LOST IN TRANSLATION 111 (2009); Steven Joffe & Franklin G.
Miller, Bench to Bedside: Mapping the Moral Terrain of Clinical Research, HASTINGS CTR.
REP., Mar.–Apr. 2008, at 30, 32, 36. It is noteworthy that the authors of the call for a
moratorium on clinical germline editing have taken this position. See Lander et al., supra
note 138, at 166 (“To be clear, our proposed moratorium does not apply to germline
editing for research uses, provided that these studies do not involve the transfer of an
embryo to a person’s uterus.”).
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It is also important to recognize that the tremendous—and
justified—scientific excitement about CRISPR and related geneediting tools may ultimately result in only modest clinical benefit,
precisely because the knowledge gains from basic and preclinical
research are themselves broadly generalizable rather than targeted to
treatment breakthroughs. This is the way all science generally works,
and despite the rapid translation of scientific excitement about gene
editing into the popular press, the science of gene editing works this
way too.
Great clinical breakthroughs could indeed come from CRISPR;
only time will tell. But progress is truly more likely if its pace is slow
and steady and if detours and switchbacks are encouraged as learning
opportunities. It may be too late to temper public expectations or
broaden public deliberation about gene editing, but reinforcing
scientific responsibility is a duty borne by all those who think about
the relationship of science to society. When shared governance is
nearly impossible to achieve or even conceive of in a global explosion
of scientific excitement and increasingly accessible technology,
sharing conversation plays a vital role in supporting and perpetuating
a global commitment to harm prevention, practical wisdom, and
reasoned reflection about medical progress.
One of the most important outcomes of the “gene-edited babies”
controversy should be renewed attention to the relationship between
good science and the ethical and social value of responsible scientific
progress. Whether or not He Jiankui is appropriately characterized as
a rogue scientist, many researchers and scholars have noted that
ethically sound research means more than simple adherence to laws
and regulations. Some have gone on to point out that critical
reflection about the ethical underpinnings of human research and the
promotion of open and robust discussion regardless of self-interest
are essential.158 After all, Dr. He appears to believe that his work is
158. See, e.g., J. Benjamin Hurlbut & Jason Scott Robert, CRISPR Babies Raise an
Uncomfortable Reality—Abiding by Scientific Standards Doesn’t Guarantee Ethical
Research, CONVERSATION (Dec. 3, 2018, 6:33 AM), https://theconversation.com/crisprbabies-raise-an-uncomfortable-reality-abiding-by-scientific-standards-doesnt-guaranteeethical-research-108008 [https://perma.cc/9B3K-RWUR]; Mark Yarborough, Who Missed
the Chance to Stop the CRISPR Babies Scientist? Look in the Mirror, STAT (Nov. 30,
2018), https://www.statnews.com/2018/11/30/missed-chance-stop-crispr-babies-scientist/
[https://perma.cc/74M9-YR2E]; see also Jon Cohen, Stanford Says Its Researchers Did Not
Help Chinese Biologist Who Gene Edited Babies, SCIENCE (Apr. 16, 2019),
https://www.sciencemag.org/news/2019/04/stanford-says-its-researchers-did-not-help-chinesebiologist-who-gene-edited-babies [https://perma.cc/9A43-35B4].

97 N.C. L. REV. 1051 (2019)

1090

NORTH CAROLINA LAW REVIEW

[Vol. 97

both ethical and necessary; the extent to which he may have
misunderstood what seems clear to others is a cautionary commentary
on ethics education in the sciences, at every level.159 The integrity of
scientific data and the ethics of translational research are
interdependent.160 Both depend upon public and policy conversations
about what constitute common human values and why we hold
them. 161 This is why careful, transparent attention to all its
implications is essential to the success of all new science. As difficult
and all consuming as that attention is, both for scientists and for the
rest of society, the promise of gene editing deserves no less.
CONCLUSION
This Article has attempted, in a drastically condensed discussion,
to describe the rapid development of gene editing and to highlight the
scientific, medical, ethical, and policy challenges posed by editing the
genomes of embryos destined to be born. Such edits are expected to
be inherited by future generations. Although developing effective
genetic treatments for already-born persons is universally desirable,
inheritable genetic changes have been prohibited or, at best, regarded
with extreme caution, for a variety of ethical, policy, and scientific
reasons, including concern about the high likelihood of dangerous
outcomes, desire to make use of less drastic means of eliminating
genetic disease, and the hope of preserving the human genetic
inheritance without introducing uncontrolled enhancements.
Careful and thoughtful ongoing research can make use of
CRISPR and related editing technologies in order to learn more
about human development and disease, and thus has a promising
159. See, e.g., Sharon Begley, He Took a Crash Course in Bioethics. Then He Created
CRISPR Babies, STAT (Nov. 27, 2018), https://www.statnews.com/2018/11/27/crisprbabies-creator-soaked-up-bioethics/ [https://perma.cc/TP6F-RBEP]; Jon Cohen, After Last
Week’s Shock, Scientists Scramble to Prevent More Gene-Edited Babies, SCIENCE (Dec. 4,
2018, 5:25 AM), https://www.sciencemag.org/news/2018/12/after-last-weeks-shock-scientistsscramble-prevent-more-gene-edited-babies [https://perma.cc/99SY-ZWE9]; Vrotsos, supra
note 152. Notably, Dr. He and several coauthors, including an American public relations
specialist, authored an article in 2018 entitled “Draft Ethical Principles for Therapeutic
Assisted Reproductive Technologies.” See Retraction of: Draft Ethical Principles for
Therapeutic Assisted Reproductive Technologies by He J et al., CRISPR J 2018; Fast Track.
DOI:10.1089/crispr/2018/0051, 2 CRISPR J. 65, 65 (2019). This document, the content of
which is questionable in many ways, was published online by the CRISPR Journal before
the news about the twins became public. Id. It never made it into the relevant issue of the
journal, online or in print, and has since been taken down entirely. Id.
160. KIMMELMAN, supra note 157, at 94–95; Joffe & Miller, supra note 157, at 32.
161. See, e.g., DRESSER, supra note 145, at 116–17.
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future. However, the desire to develop inheritable genetic
modifications—including enhancements—is surprisingly strong, as He
Jiankui’s work has demonstrated. Moreover, Dr. He’s work has
shown that even if there were clear and universal agreement, there is
no global enforcement mechanism able to detect deviations
prospectively. Much depends upon continuing, clear, and complete
discussion among scientists, bioethics scholars, and policymakers
worldwide. Much also depends upon robust ethics education for
scientists as well as for the public. But the real question is whether,
after Dr. He, the genie can be put back in the bottle. Only time will
tell.
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